

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

BMJ Open

Optimizing HIV Drug Resistance Testing Laboratory Networks in Kenya: Insights from Systems Engineering Modeling

Journal:	BMJ Open
Manuscript ID	bmjopen-2023-079988
Article Type:	Original research
Date Submitted by the Author:	18-Sep-2023
Complete List of Authors:	Wang, Yinsheng; University of Washington, Department of Industrial & Systems Engineering Kingwara, Leonard; National HIV Reference Laboratory, Kenya Ministry of Health Wagner, Anjuli; University of Washington, Department of Global Health Yongo, Nashon; University of Washington Kenya Research and Training Center Hassan, Shukri ; University of Washington Liu, Shan; University of Washington, Department of Industrial and Systems Engineering Oyaro, Patrick ; Health Innovations Kenya (HIK) Patel, Rena C.; University of Washington, Division of Allergy and Infectious Diseases, Department of Medicine
Keywords:	HIV & AIDS < INFECTIOUS DISEASES, Decision Making, Health policy < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

SCHOLARONE[™] Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

terez oni

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Title: Optimizing HIV Drug Resistance Testing Laboratory Networks in Kenya: Insights from Systems **Engineering Modeling** Authors: Yinsheng Wang^{1*}, Leonard Kingwara^{2*}, Anjuli D Wagner³, Nashon Yongo⁴, Shukri Hassan³, Shan Liu¹, Patrick Oyaro⁵, Rena Patel^{3,6}

*co-first authors

Affiliations:

¹ Industrial and Systems Engineering Department, University of Washington, USA

- ² National Public Health Laboratory (NPHL), Kenya
- ³ Department of Global Health, University of Washington, USA
- ⁴ UW Kenya, Nairobi, Kenya
- ⁵ LVCT Health, Mombasa, Kenya

⁶ Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, USA ; Dιε.

- Abstract word count: 300/300
- Word count: 3986/4000
- Tables/figures: 5/5

ABSTRACT

Background: HIV drug resistance (DR) is a growing threat to the durability of current and future HIV treatment success. DR testing (DRT) technologies are very expensive and specialized, relying on centralized laboratories in most low- and middle-income countries (LMIC). Modelling for laboratory network with point-of-care (POC) DRT assays to minimize turnaround time (TAT), is urgently needed to meet the growing demand.

Methods: We developed a model with user-friendly interface using integer programming and queueing theory to improve the DRT system in Kisumu County, Kenya. We estimated DRT demand based on both current and idealized scenarios and evaluated a centralized-laboratory-only network and an optimized POC DRT network. A one-way sensitivity analysis of key user inputs was conducted.
 Results: In a centralized-laboratory-only network, the mean TAT ranged from 8.52 to 8.55 working days, and the

system could not handle a demand proportion exceeding 1.6%. In contrast, the mean TAT for POC DRT network? ranged from 1.13 to 2.11 working days, with demand proportion up to 4.8%. Sensitivity analyses showed that expanding DRT hubs reduces mean TAT substantially while increasing the processing rate at national labs had minimal effect. For instance, doubling the current service rate at national labs reduced the mean TAT by only 0.0% to 1.9% in various tested scenarios, whereas doubling the current service rate at DRT hubs reduced the mean TAT by 37.5% to 49.8%. In addition, faster batching modes and transportation were important factors influencing the mean TAT.

Conclusions: Our model offers decision-makers an informed framework for improving the DRT system using
 POC in Kenya. POC DRT networks substantially reduce mean TAT and can handle a higher demand proportions
 than a centralized laboratory-only network, especially for the children and pregnant women living with HIV, where
 there is an immediate push to use DRT results for patient case management.

rever only

KEY MESSAGES:

What is already known on this topic – Little data exists to help optimize HIV drug resistance (DR) laboratory networks in low- and middle-income countries (LMIC). Previous research has highlighted the benefits of POC testing, including increased patient satisfaction, improved adherence to treatment plans, and reduced healthcare costs, in early infant diagnosis and viral load testing in HIV. However, less is known about the role of POC HIV DR testing (DRT) in optimizing laboratory networks.

What this study adds – This study introduces a novel model, utilizing integer programming and queueing theory, for optimizing the laboratory network for the DRT system in Kisumu County, Kenya. The model incorporates a user-friendly interface and evaluates the DRT demand under different scenarios. It compares the performance of the current centralized-laboratory-only network with an optimized network that includes POC DRT. The sensitivity analyses provide valuable insights on key parameters of the optimized DRT network.

of the current centralized-laboratory-only network with an optimized network that includes POC DR1. The sensitivity analyses provide valuable insights on key parameters of the optimized DRT network. How this study might affect research, practice, or policy – The findings of this study can guide decision makers to prioritize the introduction and placement of POC DRT machines, and explore parameters, such as improved batching frequency and increased service rate, to improve their local DRT networks. The tool we developed can also help decision makers assign the optimal referral network fixing the known parameters. rice ra. optimal refer...

1 In Kisumu County's healthcare system, there are a total of 146 healthcare facilities that collect both HIV VL and 2 DRT samples.²³ After collecting samples from patients, each facility currently sends their samples to one of three 3 central labs (KEMRI CDC HIV/R Laboratory, AMPATH Care Laboratory, and KEMRI/Walter Reed CRC Lab) for 4 HIV VL testing. Once results are returned, patients deemed to not reach viral suppression (defined as VL<200 5 copies/ml per 2022 Kenya MoH HIV treatment guidelines) undergo discussion with a multidisciplinary team at 6 the facilities,²⁴ enhanced adherence counseling, including at times directly observed therapy, assessment of and 7 addressing any other causes of viremia, and then repeat VL testing performed three months after the initial 8 viremic episode detection and assurance of enhance adherence efforts.¹⁵ If the patient still has viral non-9 suppression at repeat VL testing, then providers consult a national-level technical working group to seek advice-10 on DRT. Once that working group reviews the case and approves DRT, the patient is called back to the facility 11 to have another blood sample taken for DRT. This sample is currently sent to one facility, the National Public? 12 Health Laboratory (NPHL), to conduct DRT, which it conducts for the entire country for the public sector. While 2 13 private sector DRT may occur in other facilities, it likely only represents a minority of the DRT occurring in the 14 country. For DRT, the national level laboratory NPHL utilizes Sanger 3730xl for consensus sequencing of 15 samples, which can theoretically process up to 200 samples/day with a more realistic throughput of 100 16 17 samples/day based on the available human resource and instrumentation available. 18

Currently, no POC DRT options are available commercially in Kenya. Our research team has been involved with 19 20 a field validation of a novel, POC DRT option called OLA Simple.¹⁵⁻¹⁷ From March to June 2021, we piloted this 21 technology at two of the facilities mentioned above, KEMRI CDC HIV/R Laboratory and NPHL. Based on the 22 technical lessons learned from that field validation, we have deemed that the current iteration of the POC DRT 23 platform of OLA Simple still requires a high level of technical expertise and, therefore, can only be implemented 24 at a limited number of sites, unlike many of the POC VL testing platforms. Thus, we have purposefully selected structure of publicly accessible routines. Thus, we have purposefully selected structure of publicly accessible routines. Thus, we have purposefully selected structure of publicly accessible routines. Thus, we have purposefully selected structure of publicly accessible routines. Thus, we have purposefully selected structure of publicly accessible routines. Thus, we have purposefully selected structure of publicly accessible routines. Thus, we have purposefully selected structure of publicly accessible routines. Thus, we have purposefully selected structure of publicly accessible routines. Thus, we have purposefully selected structure of publicly accessible routines. Thus, we have purposefully selected structure of publicly accessible routines. Thus, the three existing and the addition of the POC DRT has proven challenging due to the structure of publicly accessible routines. at a limited number of sites, unlike many of the POC VL testing platforms. Thus, we have purposefully selected $\hat{\mathbf{g}}$ 25 26 27 28 29 30 31

33

35 data and the difficulties associated with using individual-level data, including issues with ID tracking. In addition. 36 missing data and inconsistencies were observed to varying degrees depending on the characteristic.²⁶ As a 37 38 result, it is necessary to use estimated proportion of receiving DRT among HIV+ people to approximate the DRT 39 demand. 40

41 To incorporate a range of possibilities for the demand of DRT, we considered the following two scenarios based 42 on the overall Kenya MoH HIV treatment guidelines (Figure 1).24 For Scenario 1, we model the status-quo or 43 current DRT demand based on existing data on high VLs from the available data for Kisumu County from the Kenya MoH HIV VL dashboard.²⁷ We propose a range of demand values that includes an upper estimate based 44 45 on the assumption of perfect adherence to the 2022 Kenyan guidelines. This approach is motivated by the 46 observation that the current demand for DRT may underestimate the true need for the service. In the figure, the 47 blocks colored blue represent the chain leading to DRT, with the green blocks showing variable rates. Weg 48 computed the DRT proportion with combinations of the two varying parameters of (1) percentage of the second 49 VL being conducted (range 25-100%) and (2) the 2nd VL being >1000 copies/ml (range 25-75%). The estimated 50 proportion of receiving DRT under Scenario 1 ranges from 0.40% to 4.80%. Details of the calculation process 51 can be found in Supplementary Table 2. For Scenario 2, we consider a more idealized case scenario where DRT 52 is recommended earlier in algorithm management, and therefore, chose a lower VL level and earlier step in VL 53 54 monitoring to conduct DRT, akin to high-income country settings, where DRT is done at first detection of viremia 55 (e.g., DRT requested at 1st VL >200 copies/ml). This scenario has no variable rates. Of note, while the most 56 recent Kenya MoH HIV treatment guidelines generally recommend using a VL cutoff threshold of >200 copies/ml 57 as non-suppression, unfortunately, estimates of DRT demand are only available for VL as low as 400 copies/ml. 58 The estimated proportion of receiving DRT under Scenario 2 is 14.62%.

32

2.4 Data Acquisition

Our team collected model parameter information through collaboration with Kenyan policymakers and laboratory specialists. Table 1 lists all model parameters we used in the model, base case values, and their data sources. As a baseline case, we assumed that samples are sent once a week to the national laboratory and daily to other POC DRT hubs by each facility, using motorbikes as the transportation mode, under average road and weather conditions. To test the results under various settings, we conducted one-way sensitivity analyses on several key parameters, including the operational capacity of the national laboratory, the number of machines in hubs, batching mode, and transportation parameters. Protected

2.5 Model: Optimization and Queueing Model

This section outlines the formulation of our optimization model, including decision variables, constraints, and objectives. The primary goal of the model is to improve the total turnaround time of the whole testing system by greorganizing the referral network. Further information about the mathematical expressions used in the model can be found in the Part 3 of Supplementary materials.

The decision variable is a binary referral indicator (i.e., 0 or 1) which connects each facility with testing demand and a potential service site. If their referral indicator is equal to 1, it means the corresponding facility sends their $\overline{\mathbf{a}}$ testing samples to that service site. Two constraints are considered for both demand and supply sides. For the demand side, there is one constraint ensuring that each testing demand is met, and the samples are assigned of to only one testing facility. For the supply side, the total number of accepted samples for the national laboratory and POC DRT hubs should not exceed its capacity.

The objective of the model is to minimize the overall time it takes to process the DR testing samples across all 146 facilities. This time is made up of three parts: the time it takes for a facility to prepare and send the samples (batching delay), the time it takes for the samples to be transported to the testing site (transportation time), and the time it takes for the samples to be processed at the testing site (processing time).

The processing time in the DRT laboratories was analyzed using queueing models, which are used to represent at a mericipation of the processing time in the DRT samples at each selected laboratory.²⁵ Two separate queues were built to reflect the processes: (1) entering samples into the computer system and sample preparation and (2) testing process. The processing time in the system is the sum of these two queueing times. For practical use, we focused on optimizing two factors - batching delay time and transportation time - in the objective function and add heuristic constraints on utilization rate, avoiding extremely large service time. Details of Excel Decision Support Tool can be found in Part 4 of Supplementary materials. **3.0 RESULTS** The section is organized as follows: Section 3.1 provides a statistical summary of the performance of the system in turnaround time under varying DRT rates; in section 3.2, we visualize the facilities and referral networks on a map; and section 3.3 focuses on the sensitivity analyses for several important operational parameters.

ō ğ

For our following analysis, we compared two different networks: the first network only involved the national laboratory, while the second network introduced four POC DRT laboratories in addition to the national laboratory. We tested both networks in combination with the two different DRT rate estimation scenarios.

3.1 Turnaround Time

We assumed that all samples within a facility would have the same expected turnaround time. By taking the average of the turnaround times per sample from all 146 facilities, we calculated the mean turnaround time. This metric was used to assess the performance of each facility under different conditions. Under the national-laboratory-only network, when DRT rate ranges from 0.4% to 1.2%, the mean turnaround time for all facilities is

about 9 working days, which is consistent with the current observed turnaround time (per unpublished, internal data from NPHL). However, as the DRT rate increases and reaches 1.6%, demand exceeds capacity and waiting times become excessively long, rendering the model infeasible. By contrast, when POC DRT hubs are added to the network, the mean turnaround time reduces to between 1.13 and 2.11 working days, substantially improving system efficiency. The POC DRT hubs network remains feasible until the DRT rate reaches 4.8%, at which point the addition of more POC machines or improvements to the capacity of the national laboratory would be needed to meet the DRT demand. Of note, our results show that as the DRT rate increases, the mean turnaround time exhibits a monotonically increasing trend for both networks. In the POC DRT hubs model, when POC DRT hub capacity is insufficient to meet demand, samples are re-routed to national laboratory. As presented in Table 2, the increase in the DRT rate to 2.4% is associated with a marked surge in the standard deviation of turnaround 10 time from 0.05 to 0.87 working days, as well as an escalation in the maximum of turnaround time from 1.71 to 8.56 working days. **3.2 Referral Network Maps** We present a visualization of the referral network, highlighting both national laboratory and POC DRT hubs in 11 12

14

1

2

3

4

5

6

7

8

9

13

33

35

15 16 17 Figure 2. The visualizations are organized into different levels of DRT rate (0.4%, 1.2%, 3.6%), each with one 18 plot displaying the complete map encompassing all facilities in Kisumu County. When DRT rate is 3.6%, we 19 provide an additional plot zooming into facilities surrounding Kisumu city to reflect the involvement of the national 20 lab when DRT rate grows. The figure does not contain a panel showing the national-laboratory-only network, 21 since all samples are directed to that laboratory. Typically, facilities forward samples to the POC DRT hub closesta 22 to their location, with exceptions arising due to limited capacity at the nearest testing hub. At DRT rates of 0.4% of 23 and 1.2%, the referral network is similar, with demand for DRT largely being handled by three POC DRT hubse 24 (KEMRI CDC HIV/R Laboratory, KEMRI/Walter Reed CRC Laboratory, and JOOTRH). At these two levels of DRT rate, the AMPATH Care Laboratory and the national laboratory do not receive any samples from Kisumu County, presumably due to high transportation times. When the DRT rate increases to 3.6%, the referral network expands to incorporate both the AMPATH Care Laboratory and the national laboratory. More specifically, when the DRT demand proportion ranges from 0.4% to 1.6%, no facilities send samples to the national lab. However, the DRT demand proportions are 2.4%, 3.2%, and 3.6%, 2, 6, and 9 facilities out of 146, respectively, send samples to the national lab. Those facilities sending their samples to NPHL face substantially longer turnaround times due to the extended transportation and batching times. (KEMRI CDC HIV/R Laboratory, KEMRI/Walter Reed CRC Laboratory, and JOOTRH). At these two levels of \$ 25 26 27 28 29 30 31 32

3.3 One-Way Sensitivity Analyses 34

Table 3 outlines the mean turnaround time of all facilities under three different settings for each parameter, as 36 well as their percentage change compared with the baseline results. We ground these changes at a DRT demand rate of 1.2% with the national-laboratory only model, 1.2% with adding four POC DRT hubs model, and 3.6% 37 38 39 with the latter model. For quick visualization, a gray scale captures the magnitude of change from baseline. 40

Batching delay mode had the most substantial impact on the mean turnaround time in the national-laboratory-41 42 only network. Specifically, when transitioning from a weekly to a twice-a-week or daily batching delay mode, the 43 mean turnaround time decreased by 34.3% or 80.1%, respectively. In both the national laboratory and POC DRT 44 hubs networks, we observed that adding machines or improving the machine service rate also improved the 45 system's efficiency. For example, the addition of two machines for all existing hubs led to a 40.8% reduction in 46 turnaround time. On the other hand, increasing the operational capacity of national laboratory had a minor impact 47 on the mean turnaround time under all settings, suggesting that expanding the capacity of the national laboratory, 48 (e.g., by adding more machines or human resources) would not substantially improve the system's efficiency. Ing 49 addition, road and weather conditions had negligible effects on the mean turnaround time in all scenarios, while 50 transportation mode had a more substantial impact on the turnaround time, particularly with walking sample 51 delivery—an unlikely scenario—compared to a baseline of motorbike transport (93.5% slower). However, car 52 transport was not meaningfully better (only 2.7% faster) compared to motorbike transport. 53

55 **4.0 DISCUSSION** 56

57 Our modeling study, employing systems engineering methodologies, reveals that POC DRT is likely to be 58 required in addition to centralized laboratory testing to realize the demand for DRT in LMICs in the upcoming

BMJ Open

years. The existing strategy, in which a solitary national laboratory is responsible for conducting DRT for the 1 entire laboratory network, will rapidly encounter capacity limitations if the DRT demand were to merely triple from 2 0.4% to 1.2%. The new configuration of a POC DRT network is designed to accommodate up to a ninefold 3 escalation in the baseline rate, from 0.4% to 3.6%. As noted previously, despite marked enthusiasm for 4 dolutegravir-containing regimen use in LMICs, DR will be an enduring concern. DR to dolutegravir is already 5 emerging,^{9,28-32} and because it remains unclear what regimens should be utilized in cases of dolutegravir 6 resistance, the use of DRT is only going to increase as surveillance for dolutegravir resistance intensifies in 7 LMICs. Though the maximum potential DRT demand rate (14.6%) modeled in our Scenario 2 is highly 8 improbable to occur in LMICs in the foreseeable future, there is a pressing need for a substantial increase in 9 centralized and POC DRT capacity to cope with the likely upsurge in DRT demand. This increase in capacity will 10 be critical to ensuring that LMICs are able to effectively manage the growing need for HIV DR test especially 11 among the children and pregnant women living with HIV that are more sensitive to return of results. 12

One of the largest determinants of turnaround time was the batching delay. For instance, increasing the sample 14 15 transportation frequency from a weekly to a twice-weekly basis could potentially halve the turnaround time. Furthermore, if samples were transported daily, the turnaround time could be halved once again, potentially 16 17 resulting in more efficient and timely processing of samples. Of course, a trade-off between the cost and labor 18 of frequent shipment against economies of scale of batching need to be considered when determining the batching delay for transport of samples from a spoke to a hub facility. By having closer POC DRT facilities to the 19 20 spoke facilities than the national laboratory, this issue of batching delay is overcome by a network that includes 21 POC DRT hubs. Since direct data about the impact of POC DRT testing on results utilization has not been 22 studied, parallels with POC VL testing may be useful: although POC VL testing has not necessarily consistently 23 improved viral suppression,^{33–35,21} improved turnaround times are highly motivating for providers and patients³⁶ 24 and results utilization appears to improve as well.^{20,34,37} 25

26 Another important factor influencing turnaround time is the service rate or operational capacity of POC machines. 27 This expansion of POC machines may lead to very efficient and timely delivery of test results (possibly within 28 one day). However, our study suggests that augmenting the operational capacity of the national laboratory does 29 not have a substantial impact on reducing the mean turnaround time for DRT. This is because facilities continue 30 to experience substantial delays due to the long transport and batching delays involved in sending samples to 🗒 🖲 31 the national laboratory. Furthermore, since the national laboratory has a limited capacity share reserved for the Kisumu County to process samples from other parts of the country, it is fundamentally limited in improving 32 33 turnaround times for the region. While we did not explicitly model the additive improvements in both increasing 34 35 the operational capacity at the centralized laboratory and reducing the batching delays, were those factors more easily modifiable for a given national laboratory, it is possible that a national laboratory network could be 36 responsive to the increasing needs of increasing DRT demand over time. Therefore, decision-makers should 37 38 consider focusing on optimizing POC machine capacity as a potentially more effective approach to improve the 39 overall performance of the DRT network. 40

Given our findings, we suggest that decision makers should prioritize the introduction of POC DRT machines to 41 42 meet the current and anticipated demand for DRT in Kisumu County.7 This would effectively reduce the 43 turnaround time and offer several programmatic advantages. POC has been shown to increase patient satisfaction and adherence,³⁸ reducing healthcare costs by minimizing multiple clinic visits for result inquiries.³⁹ 44 45 Implementing POC DRT hubs addresses access disparities for marginalized communities facing limited 46 investments and ensures proper chain of custody, mitigating specimen rejection and errors in centralized referral 47 networks.^{40,41} Onsite POC testing significantly reduces the risk of poor results, enhancing clinical follow-up and 48 confidence in laboratory systems. Additionally, it may be beneficial for decision makers to explore the possibility? 49 of improving the frequency of batching samples to the national laboratory and substantially increasing the service 50 rate of POC machines as potential next steps to further enhance the system's performance. Since any of the 51 options should include investing in staff training and development programs, it is important to acknowledge that 52 determining the most efficient use of limited resources to achieve optimal results should be based on a further 53 54 cost-effectiveness analysis.

Despite unique insights yielded by our model, there are several limitations to this work. First, one of the biggest
 challenges in selecting POC DRT hubs for DRT is the intrinsic laboratory capacity for that hub to handle the
 more technical elements related to HIV DR vs. VL testing. This immediately limits the pool of candidate hubs to

60

a few select facilities already functioning at a relatively high laboratory capacity. Second, the model utilizes VL demand data from 2019, as more recent data may be affected by COVID-19-related VL testing reagent shortages. Third, in this queuing model approach, we consider time delays as one component of costs; however, the models still lack explicit parameterization for monetary costs. Fourth, future models could model clinical decision-making parameters, such as results utilization, to better demonstrate utility of such models. Finally, this model is limited to the service delivery level of Kisumu County and would require expansion for it to be applicable in other counties.

5.0 CONCLUSIONS

> In conclusion, our findings provide a valuable framework for improving the current DRT laboratory network system in Kenya, offering decision makers an opportunity to identify ways forward for DRT demand estimation, optimal referral networks and identifying key factors like transportation delays and operational capacity of POC DRT hubs. As the demand for DRT is expected to increase, we recommend the inclusion of POC DRT hubs to handle a larger volume of samples within an acceptable turnaround time.

> > or oppression of the second

Table 1: Model parameters, assumptions, and data sources.

Parameter	Base Case Value	Note
HIV VL test demand (per working	g day)	
HIV VL Testing demand in 146 facilities	Ranges from 0 to 37 (per working day) for different facilities	The quantity of VL samples from each facility is determined throu the HIV client volume data from 2019 in Kisumu County's DHIS II. Th was necessary because of the COVID-19 pandemic-relat interruptions in 2020 and the subsequent nationwide interruptions VL testing. Details of these estimations can be found in our relat work on HIV VL testing. ²²
		Data Source: http://kmhfl.health.go.ke/ and https://dhis2.org/
DRT rate	'	
Scenario 1	0.40%~4.80%	Proportion of valid VL tests unsuppressed at VL≥1000 copies/ threshold * Percentage completing second VL testing * Percentage second VL≥1000 copies/ml. Details of the data source can be found Supplementary Table 1, and calculation process with parameter combinations can be found in Supplementary Table 2.
		Data Source: https://viralload.nascop.org/
Scenario 2	14.62%	Proportion of valid VL tests unsuppressed at VL \geq 200 copies/ threshold. Of note, we changed the threshold from new recommended 200 to 400 copies/ml since the data provided does n enumerate values at the 200 copies/ml threshold. ²⁴
HIV DR test demand (per workin	g day)	
HIV DRT demand in 146 facilities under Scenario 1	Minimum demand is 0; maximum demand ranges from 0 to 2	HIV VL test demand * DRT rate
HIV DRT demand in 146 facilities under Scenario 2	Ranges from 0 to 5	
Transportation		
Distance between all facilities to the national laboratory and POC DRT hubs (km)	0 to 370	We used Google Map API to collect the distance and time data giv the name of facilities in Kisumu, Kenya and the locations of the nation laboratory and hubs. (https://developers.google.com/maps)
Speed: (km/hour)	5 (walk), 20 (bike), 40	To coloulate the transportation time, we provided different types
	(motorbike)*, 50 (car)	
Road condition adjustment coefficient		We considered different weather and road conditions and allow users to change these conditions based on their needs. The weath
Road condition adjustment	(motorbike)*, 50 (car) 0.8 (good), 1 (average)*,	transportation modes and allowed the user to decide which one to u and estimated the average speed for each transportation mode. We considered different weather and road conditions and allow users to change these conditions based on their needs. The weath and road conditions are 'good', 'average' or 'bad', and the time need
Road condition adjustment coefficient Weather condition adjustment coefficient	(motorbike)*, 50 (car) 0.8 (good), 1 (average)*, 1.2 (bad) 0.8 (good), 1 (average)*, 1.2 (bad)	transportation modes and allowed the user to decide which one to u and estimated the average speed for each transportation mode. We considered different weather and road conditions and allow users to change these conditions based on their needs. The weath and road conditions are 'good', 'average' or 'bad', and the time need for transportation could be less given better weather and ro
Road condition adjustment coefficient Weather condition adjustment coefficient	(motorbike)*, 50 (car) 0.8 (good), 1 (average)*, 1.2 (bad) 0.8 (good), 1 (average)*, 1.2 (bad)	transportation modes and allowed the user to decide which one to u and estimated the average speed for each transportation mode. We considered different weather and road conditions and allow users to change these conditions based on their needs. The weath and road conditions are 'good', 'average' or 'bad', and the time need for transportation could be less given better weather and ro conditions. transported to testing facility (hub or national laboratory)] If the samples are sent immediately once received at the facility due
Road condition adjustment coefficient Weather condition adjustment coefficient Batching delay (min): [frequency	(motorbike)*, 50 (car) 0.8 (good), 1 (average)*, 1.2 (bad) 0.8 (good), 1 (average)*, 1.2 (bad) with which samples are t	transportation modes and allowed the user to decide which one to u and estimated the average speed for each transportation mode. We considered different weather and road conditions and allow users to change these conditions based on their needs. The weath and road conditions are 'good', 'average' or 'bad', and the time need for transportation could be less given better weather and ro conditions. transported to testing facility (hub or national laboratory)] If the samples are sent immediately once received at the facility due the scarcity of the demand, we would simply remove the aspect batching.
Road condition adjustment coefficient Weather condition adjustment coefficient Batching delay (min): [frequency Immediately	(motorbike)*, 50 (car) 0.8 (good), 1 (average)*, 1.2 (bad) 0.8 (good), 1 (average)*, 1.2 (bad) with which samples are the 0	transportation modes and allowed the user to decide which one to u and estimated the average speed for each transportation mode. We considered different weather and road conditions and allow users to change these conditions based on their needs. The weath and road conditions are 'good', 'average' or 'bad', and the time need for transportation could be less given better weather and ro conditions. transported to testing facility (hub or national laboratory)] If the samples are sent immediately once received at the facility due the scarcity of the demand, we would simply remove the aspect

Entering process			
Mean service rate (test per day) Number of servers	100 2	Mean service rate refers to the average number of DR samples received at one central laboratory given current staffing and process steps. Number of servers refers to the number of workers processing the entering of samples. We assume that there are two workers in each central laboratory working on entering the samples into the system.	
Machine process			
Mean service rate (test per day)	100	We assume each central laboratory can handle up to 500 samples per week, which in turns to be 100 samples per working day. Estimates based on personal communication with central laboratory managers.	
Number of machines at each central lab	10	Estimates based on personal communication with central laboratory managers.	
Percentage of DRT samples from Kisumu	7.9%	For 2021, 89 of 1123 DRT samples (7.925%) were from Kisumu County per personal communication with central laboratory managers.	
POC DRT hub queueing paramet	ers		
Entering process	a'		
Mean service rate (test per day)	100	Mean service rate refers to the average number of DR samples	
Number of servers	1	received at DRT hubs given current staffing and process steps. We assume that there is only one worker in each hub working on entering the samples into the system.	
Machine process			
Mean service rate (tests per day)	2	Data source: personal communication with implementing partner director for HIV programs in Kisumu County. OLA DR assay can only do two samples per working day.	
Number of servers			
Hub 1: KEMRI CDC	2	Number of servers refers to the number of machines assigned	
Hub 2: AMPATH	2	for each hub.	
Hub 3: Walter Reed CDC	2		
Hub 4: JOORTH	2		
Percentage of samples from Kisu	mu		
KEMRI CDC	100%	Given that the POC DRT hubs conduct POC DRT, we assumed all	
AMPATH	100%	samples coming to these hubs are from facilities within Kisumu County. Of note, because POC DRT will likely be based on point	
	100%	mutation detection, and not full genome sequencing, some of the samples with positive findings on POC DRT may need full genomic	
Walter Reed CDC		 sequencing via consensus sequencing at the national, cer laboratory. Our DRT demand estimates, and modeling parameter not account for these few additional DRT samples that may be nee at the national, central laboratory. 	

BMJ Open

Infea Infea Infea Infea Infea	Turnaround time, working days Min, Max 8.33, 8.70 8.33, 8.71 8.33, 8.71 8.36, 8.73 asible asible asible asible	Infea	Turnaround time, working days Min, Max 1.03, 1.30 1.04, 1.65 1.16, 1.70 1.46, 1.71 1.48, 8.56 1.49, 8.67 asible
8.53 (0.09) 8.55 (0.09) Infea Infea Infea Infea Infea	8.33, 8.71 8.36, 8.73 asible asible asible asible asible	1.35 (0.2) 1.44 (0.15) 1.53 (0.05) 1.69 (0.87) 1.90 (1.49) 2.11 (1.81) Infea	1.04, 1.65 1.16, 1.70 1.46, 1.71 1.48, 8.56 1.48, 8.60 1.49, 8.67
8.55 (0.09)	8.36, 8.73 asible asible asible asible asible	1.44 (0.15) 1.53 (0.05) 1.69 (0.87) 1.90 (1.49) 2.11 (1.81) Infea	1.16, 1.70 1.46, 1.71 1.48, 8.56 1.48, 8.60 1.49, 8.67 asible
Infea Infea Infea Infea Infea Infea	asible asible asible asible asible asible	1.53 (0.05) 1.69 (0.87) 1.90 (1.49) 2.11 (1.81) Infea	1.46, 1.71 1.48, 8.56 1.48, 8.60 1.49, 8.67 asible
Infea Infea Infea Infea Infea	asible asible asible asible asible	1.69 (0.87) 1.90 (1.49) 2.11 (1.81) Infea	1.48, 8.56 1.48, 8.60 1.49, 8.67 asible
Infea Infea Infea Infea	asible asible asible asible	1.90 (1.49) 2.11 (1.81) Infea	1.48, 8.60 1.49, 8.67 asible
Infea Infea Infea	asible asible asible	2.11 (1.81) Infea	1.49, 8.67 asible
Infea Infea	asible	Infea	asible
Infea	asible	Infea	
			asible

Table 3: Results for one-way sensitivity analyses, with mean and standard deviation of turnaround time in	
working days, and the percentage change from the baseline parameter.	

	National-laboratory-only (DRT rate: 1.2%)	National laboratory & POC DRT hubs (DRT rate: 1.2%)	National laboratory & POC DRT hubs (DRT rate: 3.6%)	
Capacity Improvement				
Improving operation capacity	of the national lab			
current service rate *	8.55 (0.09)	1.44 (0.15)	2.11 (1.81)	
1.5 times current service rate	8.52 (0.09), -0.4%	1.44 (0.15), 0.0%	2.07 (1.81), -1.9%	
2 times current service rate	8.52 (0.09), -0.4%	1.44 (0.15), 0.0%	2.07 (1.80), -1.9%	
Add machines in hubs			·	
No additional machines *	**	1.44 (0.15)	2.11 (1.81)	
Add 1 server for all existing hubs	**	1.23 (0.12), -14.6%	1.47 (0.90), -30.3%	
Add 2 servers for all existing hubs	**	1.12 (0.07), -22.2%	1.25 (0.05), -40.8%	
Improving operation capacity	of hubs			
current service rate*	**	1.44 (0.15)	2.11 (1.81)	
2 times current service rate	**	0.90 (0.07), -37.5%	1.06 (0.05), -49.8%	
4 times current service rate	**	0.73 (0.06), -49.3%	0.79 (0.08), -62.6%	
Batching delay of sending samp	les to the national lab			
Daily	1.70 (0.09), -80.1%	1.44 (0.15), 0.0%	1.61 (0.11), -23.7%	
Twice a week	5.62 (0.09), -34.3%	1.44 (0.15), 0.0%	1.89 (1.06), -10.4%	
Once a week*	8.55 (0.09)	1.44 (0.15)	2.11 (1.81)	
Transportation parameters		7		
Road/weather condition		0		
Good	8.32 (0.07), -2.7%	1.43 (0.15), -0.7%	2.06 (1.76), -2.4%	
Average *	8.55 (0.09)	1.44 (0.15)	2.11 (1.81)	
Bad	8.78 (0.11), 2.7%	1.46 (0.15), 1.4%	2.13 (1.87), 0.9%	
Transportation mode				
Walk	16.54 (0.73), 93.5%	2.04 (0.48), 41.7%	3.38 (3.73), 60.2%	
Bike	9.69 (0.18), 13.3%	1.53 (0.17), 6.3%	2.29 (2.08), 8.5%	
Motorbike *	8.55 (0.09)	1.44 (0.15)	2.11 (1.81)	
Car	8.32 (0.07), -2.7%	1.43 (0.15), -0.7%	2.06 (1.76), -2.4%	
represents baseline parame	ter settings			

0~2

BMJ Open

2~4
4~6
6~8
8~10
<u>></u> 10

to been teriew only

Acknowledgements

We thank the stakeholders who participated in focus groups and advised our study team on this modeling project.

We thank the National Public Health Laboratory, National AIDS and STI Control Program (NASCOP), Kisumu County Health Management Team, Ministry of Health, and teams who provided guidance on appropriate

parameters and data sources for this work.

Sex and/or Gender Data Disaggregation

We have not pursued sex and/or gender data disaggregation for the modeling work, as none of the modeling parameters are contingent on sex and/or gender.

- Author Reflexivity Statement Has the research team engaged constructively with the reflexivity statement? [Yes.] Have the research partners co-developed the research study? [Yes.] Does the study address priority research questions for the LMIC partner(s)? [Yes.] Is there a LMIC partner who is the first or last author? If not, what is the explanation? [Yes.] How have LMIC early career researchers been incorporated as authors? [Yes, one of the first co-authors is a LMIC partner, who was instrumental in conceptualization, data procurement, and decision to submit manuscripter.
- BMJ Open: first published as 10.1136/bmjopen-2023-079988 on 3 April 2024. Downloaded from http://bmjopen.bmj.com/ on June 12, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies. LMIC partner, who was instrumental in conceptualization, data procurement, and decision to submit manuscripti-(see more below).] How are data shared with LMIC partners to address research needs? [The data are from LMIC settings, and the model itself is shared with LMIC partners for decision-making in LMIC settings.] Is there open access funding to improve publication dissemination? [Yes.] Author Contributions: Yinsheng Wang and Leonard Kingwara contributed equally to this paper Conceptualization - Rena C. Patel, Leonard Kingwara Data programment & provision - Leonard Kingwara

- Data procurement & provision - Leonard Kingwara
- Funding acquisition Rena C. Patel, Anjuli D Wagner (MPI)
- Methodology Yinsheng Wang, Shan Liu, Anjuli D Wagner, Rena C. Patel
- Model building & Software programming Yinsheng Wang
- Supervision – Shan Liu, Rena Patel
- Visualization - Yinsheng Wang
- Writing, original draft Yinsheng Wang, Rena C. Patel
- Writing, review & editing all coauthors
- Decision to submit manuscript Yinsheng Wang, Leonard Kingwara, Rena C. Patel

Funding

This work received financial support from the National Institute of Health grant R21MH122361.

- 1. UNAIDS. In Danger: UNAIDS Global AIDS Update 2022. Geneva, Switzerland 2022.
- 2. Boerma RS, Boender TS, Bussink AP, et al. Suboptimal Viral Suppression Rates Among HIV-Infected Children in Low- and Middle-Income Countries: A Meta-analysis. Clin Infect Dis Off Publ Infect Dis Soc Am. 2016;63(12):1645-1654. doi:10.1093/cid/ciw645
- 3. Boender TS et al. Long-term Virological Outcomes of First-Line Antiretroviral Therapy for HIV-1 in Low-and Middle-Income Countries: A Systematic Review and Meta-analysis." Clinical infectious diseases : an and Middle-Income Countries: A Systematic Review and Meta-analysis." Clinical infectious diseases : an official publication of the. *Infect Dis Soc Am Vol 619 2015 1453-61 Doi101093cidciv556*. Published online 2015.
 4. Turkova A; et al. Dolutegravir as first- or second-line treatment for HIV-1 infection in children. *N Engl J Medg*
- 5. UNAIDS. Understanding Fast-Track: Accelerating Action to End the AIDS Epidemic by 2030.; 2021.
- 6. UNITAID HIV Nov 2015 Dx Landscape-1.pdf. Accessed May 11, 2023.
- Turkova A; et al. Dolutegravir as first- or second-line treatment for HIV-1 infection in children. N Engl J Medg

 2021 Dec 30 3852531 Httpsdoiorg101056NEJMoa2108793. Published online 2021.

 UNAIDS. Understanding Fast-Track: Accelerating Action to End the AIDS Epidemic by 2030.; 2021.

 UNITAID_HIV_Nov_2015_Dx_Landscape-1.pdf. Accessed May 11, 2023.

 http://www.unitaid.org/assets/UNITAID_HIV_Nov_2015_Dx_Landscape-1.pdf

 Scallon A, Hassan S, Qian SRW, et al. I feel drug resistance testing was giving us an aspect of making an informed decision": Qualitative insights on the role of HIV drug resistance mutations testing among children and pregnant women living with HIV in western Kenya. Press.

 7. Scallon A, Hassan S, Qian SRW, et al. I feel drug resistance testing was giving us an aspect of making an
- 8. Global action plan on HIV drug resistance 2017–2021. Accessed March 27, 2023. https://www.who.int/publications/i/item/978-92-4-151284-8
- 9. Paton NI MJ. Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial. Lancet HIV 202296e381-E393. Published online 2022.
- 10. Paton NI, Musaazi J, Kityo C, et al. Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV. N Engl J Med. 2021;385(4):330-341. doi:10.1056/NEJMoa2101609
- 11. Kouamou V, Inzaule S, Manasa J. Dolutegravir drug-resistance monitoring in Africa. Lancet HIV. 2021;8(11):e664-e666. doi:10.1016/S2352-3018(21)00268-X
- 12. da Silva J PS. Monitoring Emerging Human Immunodeficiency Virus Drug Resistance in Sub-Saharan Africa in the Era of Dolutegravir. J Infect 20222253364-366. Published online 2022.
- 13. Geneva: World Health Organization; 2022. Priorities for antiretroviral drug optimization in adults and children: report of a CADO, PADO and HIVResNet joint meeting. Licence: CC BY-NCSA 3.0 IGO.
- 14. Chua RJ, Capiña R, Ji H. Point-of-Care Tests for HIV Drug Resistance Monitoring: Advances and Potentials. Pathogens. 2022;11(7):724. doi:10.3390/pathogens11070724
- 15. Panpradist N BI. OLA-Simple: A software-guided HIV-1 drug resistance test for low-resource laboratories. EBioMedicine 2019 Dec5034-44 Doi 101016jebiom201911002 Epub 2019 Nov 22 PMID 31767540 PMCID PMC6921160. Published online 2019.
- 16. Panpradist N, Beck IA, Ruth PS, et al. Near point-of-care, point-mutation test to detect drug resistance in HIV-1: a validation study in a Mexican cohort. AIDS. 2020;34(9).

17. Vrana JD, Panpradist N, Higa N, et al. Implementation of an interactive mobile application to pilot a rapid 1 assay to detect HIV drug resistance mutations in Kenya. PLOS Glob Public Health. 2022;2(2):e0000185. 2 doi:10.1371/journal.pgph.0000185 3 4 18. Pham MD, Nguyen HV, Anderson D, Crowe S, Luchters S. Viral load monitoring for people living with HIV 5 in the era of test and treat: progress made and challenges ahead - a systematic review. BMC Public 6 Health. 2022;22(1):1203. doi:10.1186/s12889-022-13504-2 7 8 19. Pai N. Barriers to Implementation of Rapid and Point-of-Care Tests for Human Immunodeficiency Virus 9 Infection: Find Syst Rev 1996-2014 Point Care 143 81-87. Published online 2015. 10 11 20. Drain PK. Point-of-care HIV viral load testing combined with task shifting to improve treatment outcomes 12 (STREAM): findings from an open-label, non-inferiority, randomised controlled trial. Lancet HIV 74 E229-13 E237. Published online 2020. 14 15 21. Patel RC, Oyaro P, Thomas KK, et al. Point-of-care HIV viral load and targeted drug resistance mutation 16 testing versus standard care for Kenvan children on antiretroviral therapy (Opt4Kids): an open-label, 17 randomised controlled trial. Lancet Child Adolesc Health. Published online August 17, 2022. 18 19 doi:10.1016/S2352-4642(22)00191-2 20 21 22. Wang Y, Wagner AD, Liu S, et al. Using queueing models as a decision support tool for policymakers to 22 allocate point-of-care HIV viral load testing machines in Kenya. Rev. Published online 2023. 23 24 23. Kenya Master Health Facility List: Find all the health facilities in Kenya. Accessed May 8, 2023. 25 https://kmhfl.health.go.ke/#/home 26 27 24. National AIDS & STI Control Programme (NASCOP). Kenya HIV Prevention and Treatment Guidelines. 28 29 25. Hillier FS, Lieberman GJ. Introduction to Operations Research. McGraw-Hill Education; 2015. 30 31 26. Mwau M, Syeunda CA, Adhiambo M, et al. Scale-up of Kenya's national HIV viral load program: Findings 32 and lessons learned. PLoS One. 2018;13(1):e0190659. doi:10.1371/journal.pone.0190659 33 34 27. NASCOP. NASCOP Viral Load Dashboard. Accessed March 27, 2023. https://viralload.nascop.org/ 35 36 28. Loosli T, Hossmann S, Ingle SM, et al. HIV-1 drug resistance in people on dolutegravir-based ART: 37 Collaborative analysis of cohort studies. MedRxiv Prepr Serv Health Sci. Published online April 5, 38 2023:2023.04.05.23288183. doi:10.1101/2023.04.05.23288183 39 40 29. Han YS, Mesplède T, Wainberg MA. Differences among HIV-1 subtypes in drug resistance against 41 integrase inhibitors. Infect Genet Evol J Mol Epidemiol Evol Genet Infect Dis. 2016;46:286-291. 42 doi:10.1016/j.meegid.2016.06.047 43 44 30. Brenner BG, Thomas R, Blanco JL, et al. Development of a G118R mutation in HIV-1 integrase following a 45 switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors. J Antimicrob 46 47 Chemother. 2016;71(7):1948-1953. doi:10.1093/jac/dkw071 48 49 31. Ngoufack Jagni Semengue E, Santoro MM, Ndze VN, et al. HIV-1 integrase resistance associated 50 mutations and the use of dolutegravir in Sub-Saharan Africa: A systematic review and meta-analysis. 51 PLOS Glob Public Health. 2022;2(10):e0000826. doi:10.1371/journal.pgph.0000826 52 53 32. Collier DA, Monit C, Gupta RK. The Impact of HIV-1 Drug Escape on the Global Treatment Landscape. 54 Cell Host Microbe. 2019;26(1):48-60. doi:10.1016/j.chom.2019.06.010 55 56 33. Fairlie L. More frequent viral load testing, with point-of-care tests has no impact on viral suppression in 57 postpartum HIV-positive women in a randomized controlled trial in two clinics in Johannesburg. South 58 Africa. J Int AIDS Soc Vol 24 No S4 Pp 14 Gale OneFile Health Med 59 For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml 60

- 34. Chang C AO. Clinical Outcomes in a Randomized Controlled Trial Comparing Point-of-Care Versus Standard HIV Viral Load Monitoring in Nigeria. Clin Infect 2022 Jul 22ciac605 Doi 101093cidciac605 Epub Ahead Print PMID 35867672. Published online 2022.
- 35. Patel RC. Impact of point-of-care HIV viral load and targeted drug resistance mutation testing on viral suppression among Kenyan children on antiretroviral therapy: Results from an open-label, randomized controlled trial (Opt4Kids). Unpubl Manuscr. Published online 2022.
- 36. Qian SRW, Hassan SA, Scallon AJ, et al. "After viral load testing, I get my results so I get to know which path my life is taking me": qualitative insights on routine centralized and point-of-care viral load testing in western Kenya from the Opt4Kids and Opt4Mamas studies. BMC Health Serv Res. 2022;22(1):1540. doi:10.1186/s12913-022-08593-z
- 37. Jain V et al. RAPID-VL intervention improves viral load ordering, results turnaround time and viral suppression: a cluster randomized trial in HIV clinics in Uganda. 11th Int AIDS Soc Conf HIV Sci Abstr OALD01LB03 2021. Published online 2021.
- 38. Lilly CM, Ensom E, Teebagy S, et al. Patient Preferences for Point-of-Care Testing: Survey Validation and Results. Point Care. 2020;19(4):112-115. doi:10.1097/poc.000000000000214
- 39. Lucas SM. Current & Future Applications of Point-of-Care Testing.
- 40. Katoba J, Kuupiel D, Mashamba-Thompson TP. Toward Improving Accessibility of Point-of-Care Diagnostic Services for Maternal and Child Health in Low- and Middle-Income Countries. Point Care. 2019;18(1):17-25. doi:10.1097/POC.000000000000180
- 41. Plebani M. Does POCT reduce the risk of error in laboratory testing? Clin Chim Acta Int J Clin Chem. 2009;404(1):59-64. doi:10.1016/j.cca.2009.03.014


Legend of Figures

Figure 1: Scenario 1 (current DRT based on existing VL data from 2019) and 2 (more idealized DRT) flowchart for DRT demand estimation for Kisumu County, Kenya.

Note:

- 1. Color Schematic: In both Scenarios 1 and 2, blue colored blocks are utilized to illustrate the trajectory of HIV samples that lead to DRT at the final stage, in accordance with various guidelines. In Scenario 1, green colored blocks are employed to signify the consideration of various rates for conducting a second VL test and the suppressing rate for the second VL.

2. Data source: NASCOP VL database¹¹. Details of data used can be found in Supplementary Table 1. Figure 2: Referral network when POC DRT hubs are included in the testing network, with varying DRT rates and zoom levels. The markers with colors of red and blue correspond to national and four POC DRT hubs, by respectively. Additionally, blue dots are used to represent 146 facilities. The network is shown through links between facilities and selected DRT laboratories. and zoom levels. The markers with colors of red and blue correspond to national and four POC DRT hubs, e dots d DRT laborat.



339x215mm (144 x 144 DPI)



Page 22 of 32

BMJ Open: first published as 10.1136/bmjopen-2023-079988 on 3 April 2024. Downloaded from http://bmjopen.bmj.com/ on June 12, 2025 at Agence Bibliographique de I Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open

Do second viral load

testing

Not do second viral

load testing

Do second viral load testing: 25-100%

Not do second viral load testing

Drug resistence testing: 14.62%

333x176mm (144 x 144 DPI)

Viral load<1000 copies/ml (Supression): 94%

Viral load>=1000 copies/ml

Viral load<200 copies/ml (Supression): 85.38%

Viral load>=200 copies/ml (Unsupression): 14.62%

(Unsuppression): 6.4%

Viral load<1000 copies/ml

Viral load>=1000


copies/ml

Viral load<1000 copies/ml

Viral load>=1000

copies/ml: 25-75%


Drug resistence sting: 0.40% - 4.80%



Fotal VL tests done:	153,118		
Routine VL Tests with Valid Outcomes:	143,323	Proportion of Routine VL Tests with Valid Outcomes:	93.60%
Viral Load > 1000 copies/ml:	9,168	Proportion of Tests with Viral Load \geq 1000 copies/ml:	6.40%
Viral Load < 1000 copies/ml:	134,155	Proportion of Tests with Viral Load < 1000 copies/ml:	93.60%
Viral Load < 400 copies/ml:	122,364	Proportion of Tests with Viral Load < 400 copies/ml:	85.38%
Viral Load 401 - 999 copies/ml:	11,791	Proportion of Tests with Viral Load 401 - 999 copies/ml:	8.23%
Confirmatory Repeat Tests:	8,042	Proportion of Confirmatory Repeat Tests:	5.25%
Viral Load <u>></u> 1000 copies/ml:	2,309	Proportion of Tests with Viral Load \geq 1000 copies/ml:	28.71%
Viral Load < 1000 copies/ml:	5,733	Proportion of Tests with Viral Load < 1000 copies/ml:	71.29%
Baseline VLs:	1,753	Proportion of Baseline VLs:	1.14%
Viral Load ≥ 1000 copies/ml:	128	Proportion of Tests with Viral Load \geq 1000 copies/ml:	7.30%
Viral Load < 1000 copies/ml:	1,625	Proportion of Tests with Viral Load < 1000 copies/ml:	92.70%

and percentage of second VL \geq 1000 cop			
Proportion of patients receiving DRT	Percent	pies/ml	
Percentage completing second VL testing	25%	50%	75%
25%	0.40%	0.80%	1.20%
50%	0.80%	1.60%	2.40%
75%	1.20%	2.40%	3.60%
100%	1.60%	3.20%	4.80%

Supplementary Materials					
Part 1: Supplementary Tables and F	igures				
Supplementary Table 1: Parameters	for estir	nating the DRT rate			
otal VL tests done:	153,118				
Routine VL Tests with Valid Outcomes:	143,323	Proportion of Routine V	L Tests with Valid Outcom	nes:	93.60%
Viral Load ≥ 1000 copies/ml:	9,168	Proportion of Tests w	rith Viral Load ≥ 1000 cop	es/ml:	6.40%
Viral Load < 1000 copies/ml:	134,155	Proportion of Tests w	ith Viral Load < 1000 cop	es/ml:	93.60%
Viral Load < 400 copies/ml:	122,364	Proportion of Tests	with Viral Load < 400 cop	es/ml:	85.38%
Viral Load 401 - 999 copies/ml:	11,791	Proportion of Tests	with Viral Load 401 - 999	copies/ml:	8.23%
Confirmatory Repeat Tests:	3,042	Proportion of Confirmate	ory Repeat Tests:		5.25%
Viral Load <u>></u> 1000 copies/ml:	2,309	Proportion of Tests w	/ith Viral Load <u>></u> 1000 cop	es/ml:	28.71%
Viral Load < 1000 copies/ml:	5,733	Proportion of Tests w	ith Viral Load < 1000 cop	es/ml:	71.29%
Baseline VLs:	1,753	Proportion of Baseline \	/Ls:		1.14%
Viral Load ≥ 1000 copies/ml:	128	Proportion of Tests w	/ith Viral Load <u>></u> 1000 cop	es/ml:	7.30%
Viral Load < 1000 copies/ml:	1,625	Proportion of Tests w	vith Viral Load < 1000 cop	es/ml:	92.70%
Viral Load < 1000 copies/ml: ata Source: https://viralload.nascop.org/. Supplementary Table 2: DRT demands nd percentage of second VL ≥1000 c Proportion of patients receiving DRT Percentage completing second VL testing 25% 50% 75%	1	25%	50%	pies/iiii	75%
Percentage completing second VL testing		25%	0.80%		1 200/
		0.40%	1.60%		2.40%
75%		1.20%	2.40%		3.60%
100%		1.60%			5.0078
100 %			3 20%		
lote: Proportion of patients receiving DRT = P	roportion		3.20%	/ml thresho	4.80%
lote: Proportion of patients receiving DRT = P ompleting second VL testing * Percentage of s		of valid VL tests unsupp		/ml thresho	4.80%
	second V	of valid VL tests unsuppl L <u>></u> 1000 copies/ml.	ressed at VL≥1000 copies		4.80%
ompleting second VL testing * Percentage of s	second V	of valid VL tests unsuppl L <u>></u> 1000 copies/ml. GD participants (Nur	ressed at VL≥1000 copies mber of participants: ∕	12).	4.80%
ompleting second VL testing * Percentage of s	ics of F	of valid VL tests unsuppl L <u>></u> 1000 copies/ml. GD participants (Nur	ressed at VL≥1000 copies mber of participants: ∕	12).	4.80% old * Percentage R) or n (%)
ompleting second VL testing * Percentage of s Supplementary Table 3: Demographi Char	ics of F	of valid VL tests unsuppl L <u>></u> 1000 copies/ml. GD participants (Nur	ressed at VL≥1000 copies mber of participants: ∕	12). Median (IQ	4.80% old * Percentage R) or n (%)
ompleting second VL testing * Percentage of s Supplementary Table 3: Demograph Char	ics of F	of valid VL tests unsuppl L <u>></u> 1000 copies/ml. GD participants (Nur	ressed at VL≥1000 copies mber of participants: ∕	12). Median (IQ	4.80% old * Percentage R) or n (%) .5, 45)
Char Supplementary Table 3: Demographing Char Supplementary Supplementary Suppleme	ics of F	of valid VL tests unsuppl L <u>></u> 1000 copies/ml. GD participants (Nur	ressed at VL≥1000 copies mber of participants: ∕	12). Median (IQ 43 (37.	4.80% old * Percentage R) or n (%) .5, 45) 02%)
Supplementary Table 3: Demographi Char Nge Vorkstation County MOH Implementing partner	ics of F	of valid VL tests unsuppl L <u>></u> 1000 copies/ml. GD participants (Nur	ressed at VL≥1000 copies mber of participants: ∕	12). Median (IQ 43 (37. 11 (9	4.80% old * Percentage R) or n (%) .5, 45) .22%) .3%)
Supplementary Table 3: Demographi Char Age Vorkstation County MOH Implementing partner Male	ics of F	of valid VL tests unsuppl L <u>></u> 1000 copies/ml. GD participants (Nur	ressed at VL≥1000 copies mber of participants: ∕	I2). Median (IQ 43 (37. 11 (9 1 (8	4.80% old * Percentage R) or n (%) .5, 45) .22%) .3%)
Supplementary Table 3: Demographic Supplementary Table 3: Demographic Char Age Vorkstation County MOH Implementing partner Male lighest level of education	ics of F	of valid VL tests unsuppl L <u>></u> 1000 copies/ml. GD participants (Nur	ressed at VL≥1000 copies mber of participants: ∕	I2). Median (IQ 43 (37. 11 (9 1 (8	4.80% old * Percentage R) or n (%) .5, 45) .22%) .3%) .7%)
Supplementary Table 3: Demographic Supplementary Table 3: Demographic Char Age Vorkstation County MOH Implementing partner Male lighest level of education Bachelor's degree	ics of F	of valid VL tests unsuppl L <u>></u> 1000 copies/ml. GD participants (Nur	ressed at VL≥1000 copies mber of participants: ∕	12). Median (IQ 43 (37 11 (9 1 (8 8 (6)	4.80% old * Percentage R) or n (%) .5, 45) .2%) .2%) .7%) .0%)
Supplementary Table 3: Demographic Supplementary Table 3: Demographic Char Age Vorkstation County MOH Implementing partner Male Highest level of education Bachelor's degree Master's Degree	ics of F	of valid VL tests unsuppl L <u>></u> 1000 copies/ml. GD participants (Nur	ressed at VL≥1000 copies mber of participants: ∕	12). Median (IQ 43 (37) 11 (9 1 (8 8 (6) 6 (50	4.80% old * Percentage R) or n (%) .5, 45) .2%) .2%) .7%)
Supplementary Table 3: Demographi Char. Age Vorkstation County MOH Implementing partner Aale Highest level of education Bachelor's degree Master's Degree Years of education completed	ics of F	of valid VL tests unsuppl L <u>></u> 1000 copies/ml. GD participants (Nur	ressed at VL≥1000 copies mber of participants: ∕	12). Median (IQ 43 (37) 11 (9 1 (8 8 (6) 6 (5) 6 (5)	4.80% old * Percentage R) or n (%) .5, 45) .2%) .7%)
Supplementary Table 3: Demographing Supplementary Table 3: Demographing Char Age Vorkstation County MOH Implementing partner Male Highest level of education Bachelor's degree Master's Degree Years of education completed Years working with HIV treatment monitoring	second VI	of valid VL tests unsuppr L≥1000 copies/ml. GD participants (Nur	ressed at VL≥1000 copies mber of participants: ∕	12). Median (IQ) 43 (37) 11 (9 1 (8 8 (6) 6 (5) 6 (5) 6 (5) 20 (19	4.80% old * Percentage R) or n (%) .5, 45) .2%) .7%)
Supplementary Table 3: Demographic Supplementary Table 3: Demographic Char Age Vorkstation County MOH Implementing partner Male Highest level of education Bachelor's degree	urrently ir	of valid VL tests unsuppr L≥1000 copies/ml. GD participants (Nur :	ressed at VL≥1000 copies nber of participants: /	12). Median (IQ) 43 (37) 11 (9 1 (8 8 (6) 6 (5) 6 (5) 6 (5) 20 (19	4.80% old * Percentage R) or n (%) 5, 45) 02%) 0%) 0%) 0%) 0%) 0%) 0%) 0%) 0



Part 2: Formative Qualitative Research

Focus Group

The focus was on informing the DRT modeling inputs, outputs, and format, covering decision-making factors for POC technology placement, prioritization of POC machines. We recruited policymakers from county Ministry of Health teams, implementing partners, and laboratory leaders, and FGDs were conducted on Zoom in English by a trained facilitator. A set of a priori suggested model inputs informed the FGD guide, based on the co-authors' understanding of DRT systems in Kenya and engineering expertise.

Formative Input In 2021, we conducted two virtual focus group discussions with 12 HIV treatment stakeholders, comprising representatives from county ministries of health and implementing partners. Participants had experience managing clinical teams that utilized VL and DRT results for patient management, coordinating laboratory logistics, and regulatory or budgetary decision-making. A detailed description of participant demographics is provided in Supplementary Table 3 (The table is also provided as Supplementary Table 2 in our VL modeling. paper).

Overall, the processes and factors that would influence their decisions of where to place POC machines for DRT were similar to those identified for POC machines for VL testing. Generally, the decision-making process would require engagement with various stakeholders at multiple levels, from county assemblies and committees, to implementing partners, to civil society organizations. Factors that influenced participants' decisions on POC machine placement for DRT included staffing volume, facility capacity and training, geographic accessibility, disease prevalence, patient volume, and infrastructure, such as electricity and back-up power. When prioritizing the placement of POC machines, participants considered various factors such as high-volume facilities, accessibility to peripheral facilities, trained staff, and laboratory and power infrastructure. These considerations were particularly important for facilities with a high proportion of adolescents and young people who were failing to adhere to treatment.

Specifically, in reflecting on how these considerations might vary for decisions related to the placement of yet to-be developed POC DRT machines, the emphasis on the above factors shifted slightly. When considering thea placement of POC DRT machines, participants emphasized the importance of large sample volumes, accessibility to other facilities and central labs, a consistent supply of reagents, and a high-level multidisciplinary team that can run and interpret drug resistance test results.

Вu

Part 3: Mathematical Formulation for Queueing and Optimization Models

Notations

- I = 146: the number of facilities collecting samples
- I = 5: the total number of all 4 selected hubs and 1 national laboratory
- d_i : the demand at *i*-th facility per working day (7 hours/day)
- λ_i : mean arrival rate for service (testing) site j
- μ_i : mean service rate for service (testing) site *j*

 s_j : number of servers for service (testing) site j $\rho_j = \lambda_j / (s_j \mu_j)$: utilization ratio for service (testing) site j ($\rho_j < 1$). B_j : the batching delay time for service (testing) site j T_{ij} : the transportation time from facility i to service (testing) site j W_j : the expected time in service site j **Expected waiting time in Queueing Theory** M/M/s is one of the most widely studied queueing models, indicating that both the interarrival time distribution and service time distribution are Markovian (i.e., exponentially distributed). Here we used a M/M/a success to and service time distribution are Markovian (i.e., exponentially distributed). Here we used a M/M/s queue to model the arrival and processing of DR testing samples at selected hubs and national laboratory. An M/M/s queueing model has the following analytical solution for the expected time spent in the system. The mathematical formula of the expected waiting time is shown below. The mean arrival rate in service site j is $\lambda_j = \sum_{i=1}^{l} d_i x_{ij}$. The idle probability in service site *j* can be calculated as P_{0j} , where

$$P_{0j} = \frac{1}{\sum_{n=0}^{s_j-1} \frac{(\lambda_j/\mu_j)^n}{n!} + \frac{(\lambda_j/\mu_j)^{s_j}}{s_j!} (\frac{1}{1-\rho_j})}$$

Then, in conclusion, the expected waiting time for service site (hubs or central labs) j, i.e., W_j is:

$$W_{j} = \frac{P_{0j}\lambda_{j}^{s_{j}}}{(s_{j}-1)!\,\mu_{j}^{s_{j}-1}(s_{j}\mu_{j}-\lambda_{j})^{2}} + \frac{1}{\mu_{j}}$$

Optimization Formulation

≥ For modeling and optimizing the referral network, we let I = 146 be the number of facilities collecting samples, and I = 5 be the total number of selected hubs and national laboratory. To optimize the transportation cost and Ξ batching cost through re-arranging the referral network, we formulate the following optimization problem. The mathematical formula of the optimization model is shown below. Since we want to optimize the referral network and select additional hubs, the decision variables are x_{ij} . $x_{ij} = \begin{cases} 1, \text{ if } i^{th} \text{ facility sends samples to } j^{th} \text{ testing site} \\ 0, \text{ otherwise} \end{cases}$ The objective function is to minimize the total turnaround time of the system, including the total transportation of the system.

$$x_{ij} = \begin{cases} 1, \text{ if } i^{th} \text{ facility sends samples to } j^{th} \text{ testing site} \\ 0, \text{ otherwise} \end{cases}$$

time, total batching time, and total waiting time. Notice from the following objective, the total transportation time and total batching time are linear functions of the decision variables, while the waiting time is a non-linear function of the decision variables. The objective is shown by the formula below:

$$\min_{x_{ij}} \sum_{i=1}^{I} \sum_{j=1}^{J} x_{ij} T_{ij} + \sum_{i=1}^{I} \sum_{j=1}^{J} x_{ij} B_j + \sum_{i=1}^{I} \sum_{j=1}^{J} x_{ij} W_j$$

In the Excel tool, we only optimized the linear part of the objective due to computational complexities. This allows us to optimize the objective using 'Opensolver', an open-source Excel VBA add-in. Of note, in our Excel tool, we also set the maximum utilization for national laboratory as 0.9 and selected hubs as 0.7 to avoid overcrowding, which may incur extremely long wait time. In addition, we also have two constraints for the solutions. First, each

BMJ Open

facility only sends samples to one service site. Second, the total number of accepted samples in each selected site should not exceed its capacity. Mathematically, those constraints can be expressed as the following forms.
$\sum_{j=1}^{J} x_{ij} = 1 \text{for } i = 1, \dots, I$ $\sum_{j=1}^{J} x_{ij} d_i \le s_j \mu_j \text{for } j = 1, \dots, J$
$\sum_{i=1}^{J} x_{ij} d_i \le s_j \mu_j \text{for } j = 1, \dots, J$
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

<page-header><text><section-header><text><text><text><text><text><text><text><text><text><text><text>

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

$\begin{array}{cccccccccccccccccccccccccccccccccccc$	
50 57 58 59 60	

Revised Standards for Quality	y Improvement Reporting Excellence (SQUIRE 2.0)	
	September 15, 2015	

Text Section and Item Name	Section or Item Description
	The SQUIRE guidelines provide a framework for reporting new knowledge about how to improve healthcare
	• The SQUIRE guidelines are intended for reports that describe <u>system</u> level work to improve the quality, safety, and value of healthcare, and used methods to establish that observed outcomes were due to the <u>intervention(s)</u> .
	• A range of approaches exists for improving healthcare. SQUIRE may be adapted for reporting any of these.
Notes to authors	 Authors should consider every SQUIRE item, but it may be inappropriate or unnecessary to include every SQUIRE element in a particular manuscript.
	• The SQUIRE Glossary contains definitions of many of the key words in SQUIRE.
	• The Explanation and Elaboration document provides specific examples of well-written SQUIRE items, and an in-depth explanation of each item.
	• Please cite SQUIRE when it is used to write a manuscript.
Title and Abstract	
1. Title	Indicate that the manuscript concerns an <u>initiative</u> to improve healthcare (broadly defined to include the quality, safety, effectiveness, patient-centeredness, timeliness, cost, efficiency, and equity of healthcare)
2. Abstract	 a. Provide adequate information to aid in searching and indexing b. Summarize all key information from various sections of the text using the abstract format of the intended publication or a structured summary such as: background, local problem, methods, interventions results, conclusions
Introduction	Why did you start?
3. <u>Problem</u> Description	Nature and significance of the local problem
4. Available knowledge	Summary of what is currently known about the <u>problem</u> , including relevant previous studies

BMJ Open: first published as 10.1136/bmjopen-2023-079988 on 3 April 2024. Downloaded from http://bmjopen.bmj.com/ on June 12, 2025 at Agence Bibliographique de I Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

1
2
3
4
-7 5
2
6
7
8
9
10
11
12
13
14
15
16
17
18
19
19 20
21
22
23
24
25
26
27
28
29
30
31
32
33
33 34
35
36
37
38
39
40
42
43
44
45
46
47
47
49
50
51
52
53
54
55
50
57
58
59
60

5. <u>Rationale</u>	Informal or formal frameworks, models, concepts, and/or <u>theories</u> used to explain the <u>problem</u> , any reasons or <u>assumptions</u> that were used to develop the <u>intervention(s)</u> , and reasons why the <u>intervention(s)</u> was expected to work
6. Specific aims	Purpose of the project and of this report
Methods	What did you do?
7. <u>Context</u>	Contextual elements considered important at the outset of introducing the $\underline{intervention(s)}$
8. <u>Intervention(s)</u>	 a. Description of the <u>intervention(s)</u> in sufficient detail that others could reproduce it b. Specifics of the team involved in the work
9. Study of the Intervention(s)	 a. Approach chosen for assessing the impact of the <u>intervention(s)</u> b. Approach used to establish whether the observed outcomes were due to the <u>intervention(s)</u>
10. Measures	 a. Measures chosen for studying processes and outcomes of the intervention(s), including rationale for choosing them, their operational definitions, and their validity and reliability b. Description of the approach to the ongoing assessment of contextual elements that contributed to the success, failure, efficiency, and cost c. Methods employed for assessing completeness and accuracy of data
11. Analysis	 a. Qualitative and quantitative methods used to draw <u>inferences</u> from the data b. Methods for understanding variation within the data, including the effects of time as a variable
12. Ethical Considerations	Ethical aspects of implementing and studying the intervention(s) and how they were addressed, including, but not limited to, formal ethics review and potential conflict(s) of interest
Results	What did you find?
13. Results	 a. Initial steps of the <u>intervention(s)</u> and their evolution over time (<i>e.g.</i>, time-line diagram, flow chart, or table), including modifications made to the intervention during the project b. Details of the <u>process</u> measures and outcome c. Contextual elements that interacted with the <u>intervention(s)</u> d. Observed associations between outcomes, interventions, and relevant contextual elements e. Unintended consequences such as unexpected benefits, problems, failures, or costs associated with the <u>intervention(s)</u>. f. Details about missing data
Discussion	What does it mean?
14. Summary	a. Key findings, including relevance to the <u>rationale</u> and specific aimsb. Particular strengths of the project

15. Interpretation	 a. Nature of the association between the intervention(s) and the outcomes b. Comparison of results with findings from other publications c. Impact of the project on people and systems d. Reasons for any differences between observed and anticipated outcomes, including the influence of context e. Costs and strategic trade-offs, including opportunity costs
16. Limitations	 a. Limits to the <u>generalizability</u> of the work b. Factors that might have limited <u>internal validity</u> such as confounding, bias, or imprecision in the design, methods, measurement, or analysis c. Efforts made to minimize and adjust for limitations
17. Conclusions	 a. Usefulness of the work b. Sustainability c. Potential for spread to other <u>contexts</u> d. Implications for practice and for further study in the field e. Suggested next steps
Other information	
18. Funding	Sources of funding that supported this work. Role, if any, of the funding organization in the design, implementation, interpretation, and reporting

Table 2. Glossary of key terms used in SQUIRE 2.0. This Glossary provides the intended meaning of selected words and phrases as they are used in the SQUIRE 2.0 Guidelines. They may, and often do, have different meanings in other disciplines, situations, and settings.

Assumptions

Reasons for choosing the activities and tools used to bring about changes in healthcare services at the system level.

Context

Physical and sociocultural makeup of the local environment (for example, external environmental factors, organizational dynamics, collaboration, resources, leadership, and the like), and the interpretation of these factors ('sense-making ') by the healthcare delivery professionals, patients, and caregivers that can affect the effectiveness and generalizability of intervention(s).

Ethical aspects

The value of <u>system-level initiatives</u> relative to their potential for harm, burden, and cost to the stakeholders. Potential harms particularly associated with efforts to improve the quality, safety, and value of healthcare services include <u>opportunity costs</u>, invasion of privacy, and staff distress resulting from disclosure of poor performance.

Generalizability

The likelihood that the <u>intervention(s)</u> in a particular report would produce similar results in other settings, situations, or environments (also referred to as external validity).

Healthcare improvement

Any systematic effort intended to raise the quality, safety, and value of healthcare services, usually done at the <u>system</u> level. We encourage the use of this p h r a s e r a t h e r t h a n "q u a which often refers to more narrowly defined approaches.

Inferences

The meaning of findings or data, as interpreted by the stakeholders in healthcare services – improvers, healthcare delivery professionals, and/or patients and families

Initiative

A broad term that can refer to organization-wide programs, narrowly focused projects, or the details of specific interventions (for example, planning, execution, and assessment)

Internal validity

Demonstrable, credible evidence for efficacy (meaningful impact or change) resulting from introduction of a specific intervention into a particular healthcare system.

Intervention(s)

The specific activities and tools introduced into a healthcare <u>system</u> with the aim of changing its performance for the better. Complete description of an intervention includes its inputs, internal activities, and outputs (in the form of a logic model, for example), and the mechanism(s) by which these components are expected to produce changes in a <u>s y s</u> t performance.

Opportunity costs

Loss of the ability to perform other tasks or meet other responsibilities resulting from the diversion of resources needed to introduce, test, or sustain a particular improvement initiative

Problem

Meaningful disruption, failure, inadequacy, distress, confusion or other dysfunction in a healthcare service delivery system that adversely affects patients, staff, or the system as a whole, or that prevents care from reaching its full potential

Process

The routines and other activities through which healthcare services are delivered

Rationale

Explanation of why particular intervention(s) were chosen and why it was expected to work, be sustainable, and be replicable elsewhere.

Systems

The interrelated structures, people, processes, and activities that together create healthcare services for and with individual patients and populations. For example, systems exist from the personal selfcare system of a patient, to the individual provider-patient dyad system, to the microsystem, to the macrosystem, and all the way to the market/social/insurance system. These levels are nested within each other.

Theory or theories

rtheories "-ngeiavsionng" account that asserts causal Any r e l a that makes sense of an otherwise obscure process or situation (explanatory theory). Theories come in many forms, and serve different purposes in the phases of improvement work. It is important to be explicit and well-founded about any informal and formal theory (or theories) that are used.

BMJ Open

Optimizing HIV Drug Resistance Testing Laboratory Networks in Kenya: Insights from Systems Engineering Modeling

Journal:	BMJ Open
Manuscript ID	bmjopen-2023-079988.R1
Article Type:	Original research
Date Submitted by the Author:	14-Feb-2024
Complete List of Authors:	Wang, Yinsheng; University of Washington, Department of Industrial & Systems Engineering Kingwara, Leonard; National HIV Reference Laboratory, Kenya Ministry of Health Wagner, Anjuli; University of Washington, Department of Global Health Yongo , Nashon; University of Washington Kenya Research and Training Center Hassan, Shukri ; University of Washington Liu, Shan; University of Washington, Department of Industrial and Systems Engineering Oyaro, Patrick ; Health Innovations Kenya (HIK) Patel, Rena C.; University of Washington, Division of Allergy and Infectious Diseases, Department of Medicine
Primary Subject Heading :	Public health
Secondary Subject Heading:	HIV/AIDS, Health policy
Keywords:	HIV & AIDS < INFECTIOUS DISEASES, Decision Making, Health policy < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

SCHOLARONE[™] Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

reliez oni

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open

1 2 3	Title : Optimizing HIV Drug Resistance Testing Laboratory Networks in Kenya: Insights from Systems Engineering Modeling
4 5 6	Authors : Yinsheng Wang ^{1*} , Leonard Kingwara ^{2*} , Anjuli D Wagner ³ , Nashon Yongo ⁴ , Shukri A. Hassan ³ , Shan Liu ¹ , Patrick Oyaro ⁵ , Rena C. Patel ^{3,6&}
7 8	*co-first authors
9	& Corresponding author's email address: rcpatel@uw.edu
10 11 12	Affiliations:
13 14 15 16 17 18 19	 ¹ Industrial and Systems Engineering Department, University of Washington, USA ² National Public Health Laboratory (NPHL), Kenya ³ Department of Global Health, University of Washington, USA ⁴ UW Kenya, Nairobi, Kenya ⁵ LVCT Health, Mombasa, Kenya ⁶ Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, USA
20 21 22	Abstract word count: 300/300 Word count: 3986/4000, after revision: 4251 Tables/figures: 5/5
23 24	
25	
26 27	
27 28	
29	
30	
31 32	
33	
34	
35	
36 37	
38	
39	
40 41	
42	
43	
44 45	
45	
47	
48	
49 50	
51	
52	
53 54	
55	
56	
57 58	
58 59	
60	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

ABSTRACT

<u>Background</u>: HIV drug resistance (DR) is a growing threat to the durability of current and future HIV treatment success. DR testing (DRT) technologies are very expensive and specialized, relying on centralized laboratories in most low- and middle-income countries (LMIC). Modelling for laboratory network with point-of-care (POC) DRT assays to minimize turnaround time (TAT), is urgently needed to meet the growing demand.

Methods: We developed a model with user-friendly interface using integer programming and queueing theory to
 improve the DRT system in Kisumu County, Kenya. We estimated DRT demand based on both current and
 idealized scenarios and evaluated a centralized-laboratory-only network and an optimized POC DRT network. A
 one-way sensitivity analysis of key user inputs was conducted.

Results: In a centralized-laboratory-only network, the mean TAT ranged from 8.52 to 8.55 working days, and the system could not handle a demand proportion exceeding 1.6%. In contrast, the mean TAT for POC DRT network ranged from 1.13 to 2.11 working days, with demand proportion up to 4.8%. Sensitivity analyses showed that expanding DRT hubs reduces mean TAT substantially while increasing the processing rate at national labs had minimal effect. For instance, doubling the current service rate at national labs reduced the mean TAT by only 0.0% to 1.9% in various tested scenarios, whereas doubling the current service rate at DRT hubs reduced the mean TAT by 37.5% to 49.8%. In addition, faster batching modes and transportation were important factors influencing the mean TAT.

Conclusions: Our model offers decision-makers an informed framework for improving the DRT system using
 POC in Kenya. POC DRT networks substantially reduce mean TAT and can handle a higher demand proportion
 than a centralized laboratory-only network, especially for the children and pregnant women living with HIV, where
 there is an immediate push to use DRT results for patient case management.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Strengths and limitations of this study:

Strengths:

- The study utilizes a novel combination of integer programming and queueing theory to develop a userfriendly model that is specifically designed for optimizing the HIV drug resistance (DR) testing laboratory network in Kisumu County, Kenya, making it a pioneering approach in the field of HIV DR management.
- It offers a comprehensive analysis by comparing a centralized-laboratory-only network with an optimized point-of-care (POC) DR testing network, thereby providing evidence-based insights into how POC DRT can enhance system performance, particularly in terms of reducing turnaround time.

Limitations:

- While the study conducts a one-way sensitivity analysis of key parameters, it may not fully capture the complex interdependencies or the impact of multiple variables changing simultaneously, which could affect the generalizability and robustness of the model under different scenarios. It also does not include costs or budget parameters.
- The study focuses on Kisumu County, Kenya, and the findings might not be directly applicable to other regions or countries with different healthcare infrastructures, HIV prevalence rates, DRT guidelines or laboratory capabilities.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1.0 INTRODUCTION

1 2

3

4

5

6

7

8

9

HIV drug resistance (DR) is a growing threat to the durability of current and future HIV treatment success. The World Health Organization's (WHO) most recent HIV DR report in 2021 notes high concern regarding increasing pre-treatment and acquired DR, especially among children and adolescents living with HIV. Three countries, Lesotho, Uganda, and Zambia, who conducted systematic HIV DR surveillance among children and adolescents living with HIV with viral failure demonstrated high rates of nucleoside/nucleotide reverse transcriptase inhibitor (NRTI) (50-80%) and non-NRTI (84-97%) DR. Additionally, accumulation of new DR with continued viral failure has been documented in both adults and children, further limiting usable antiretroviral options.(1–4)

10 However, DR testing (DRT) technologies are very expensive and specialized, which render them a limited 11 12 resource.(5,6) Most low- and middle-income countries (LMIC) rely on centralized, highly specialized laboratories 13 and specimen transport networks to conduct DRT for a limited number of patients meeting certain criteria; current 14 low access and high turnaround times, on the order of months, limit even further use of existing DRT options.(7) 15 However, WHO endorses the need for expanded availability of DRT, including point-of-care (POC) options, and 16 acknowledges that use of new HIV treatment options will only expand this need.(8) For instance, while there is 17 marked enthusiasm for dolutegravir-containing treatment options globally, (2,9,10) resistance to dolutegravir is 18 already emerging, stressing the need to monitor dolutegravir DR urgently in LMIC.(11-13) Novel POC, or even 19 near POC, assays are on the horizon to help create greater accessibility to DRT and minimize the return of 20 results challenges often resulting from a centralized testing system. (14) Our group has been involved in the field 21 validation of one such technology called oligonucleotide ligation assay (OLA)-Simple.(15-17) Unpublished 22 Kenya HIV program data suggest better HIV viral load (VL) results utilization at POC sites than sites supported 23 by centralized laboratory testing systems, which might have implications for POC DRT use as well. 24

25 HIV treatment programs in LMIC are expanding VL testing for all people living with HIV, therefore, creating more 26 opportunities to detect viral failure.(18) It is critical to determine how to create decentralized laboratory networks 27 for DRT, possibly including POC DRT assays, to meet the anticipated increase in DRT demand. Different types 28 of decentralized laboratory network models exist in LMIC, including for HIV VL monitoring. Example networks 29 utilize hub-and-spoke or platform sharing.(19-21) Given the even more technical training and expertise needed 30 to conduct HIV DRT compared to HIV VL testing alone, platform sharing is not a likely viable option for DRT 31 32 shortly. 33

34 Given the urgent need to meet DRT demand and the specialized training required for staff, it would be beneficial 35 to model a network optimization for DRT using a hub-and-spoke framework, coupled with the application of 36 queueing theory to analyze service times. The use of optimization and queuing theory in healthcare is well-37 documented in high-resource settings for hospital and emergency department logistics(22-28). However, their 38 application in resource-limited contexts, particularly for HIV care, is emerging. (29). Studies in sub-Saharan Africa 39 highlight the prevalence of queuing issues, yet the systematic application of these models for clinical 40 improvements is still novel (30). Additionally, the deployment of POC devices for HIV testing and treatment in 41 such settings is gaining attention(31-33). 42

Thus, we aimed to develop a laboratory network optimization model based on queueing theory.First, we estimated the DRT demand for two scenarios: the current scenario of repeated VL testing with adherence counseling that leads to DRT and a more idealized scenario where DRT would be implemented under more liberal guidelines. Second, we created a model for two networks: the model of utilizing one centralized laboratory at the national level for all DRT testing for Kisumu County and an optimized network that utilized not only the national DRT laboratory but also introduced additional POC DRT hubs. We hypothesized that the second scenario with POC DRT hubs would reduce turn-around time compared to the centralized laboratory model.

52 2.0 METHODS

53 2.1 Formative Data Collection 54

To gather insights into Kenyan policymakers' preferences for model function and decision-making, we conducted
 formative qualitative research using focus group discussions (FGDs). Demographics pf FGDs participants are in
 Supplementary Table 1. Details and results can be found in Part 2 of Supplementary materials. We obtained
 ethical approval from African Medical and Research Foundation (AMREF) and Jaramogi Oginga Odinga

60

Teaching and Referral Hospital (JOOTRH) Institutional Review Boards (IRBs) in Kenya, as well as the University of Washington and the University of Colorado Denver IRBs in the United States, and all study procedures were in line with the Declaration of Helsinki. We identify the research topic as of importance to patients and service users. The policymakers we interviewed help us better understand their needs.

1

2

3

2.2 Patient and Public Involvement Statement

Our research incorporated Kenyan policymakers at the formative stage through FGDs, which informed the model's development and decision-making criteria directly relevant to patient care. These discussions were pivotal in shaping the research questions and ensuring the outcome measures reflected patient priorities and experiences.

1213 2.3 Current DRT process and selection of POC DRT hubs

14 15 In Kisumu County's healthcare system, there are a total of 146 healthcare facilities that collect both HIV VL and 16 DRT samples.(34) After collecting samples from patients, each facility currently sends their samples to one of 17 three central labs (KEMRI CDC HIV/R Laboratory, AMPATH Care Laboratory, and KEMRI/Walter Reed CRC 18 Lab) for HIV VL testing. Once results are returned, patients deemed to not reach viral suppression (defined as 19 VL<200 copies/ml per 2022 Kenya Ministry of Health (MoH) HIV treatment guidelines) undergo discussion with 20 a multidisciplinary team at the facilities, (35) enhanced adherence counseling, including at times directly observed 21 therapy, assessment of and addressing any other causes of viremia, and then repeat VL testing performed three 22 months after the initial viremic episode detection and assurance of enhance adherence efforts.(15) If the patient 23 still has viral non-suppression at repeat VL testing, then providers consult a national-level technical working 24 group to seek advice on DRT. Once that working group reviews the case and approves DRT, the patient is called 25 back to the facility to have another blood sample taken for DRT. This sample is currently sent to one facility, the 26 National Public Health Laboratory (NPHL), to conduct DRT, which it conducts for the entire country for the public 27 sector. While private sector DRT may occur in other facilities, it likely only represents a minority of the DRT 28 occurring in the country. For DRT, the national level laboratory NPHL utilizes Sanger 3730xl for consensus 29 sequencing of samples, which can theoretically process up to 200 samples/day with a more realistic throughput 30 of 100 samples/day based on the available human resource and instrumentation available. 31

32 Currently, no POC DRT options are available commercially in Kenya. Our research team has been involved with 33 a field validation of a novel, POC DRT option called OLA-Simple.(15–17,36) From March to June 2021, we 34 35 piloted this technology at two of the facilities mentioned above, KEMRI CDC HIV/R Laboratory and NPHL. Based 36 on the technical lessons learned from that field validation, we have deemed that the current iteration of the POC 37 DRT platform of OLA Simple still requires a high level of technical expertise and, therefore, can only be 38 implemented at a limited number of sites, unlike many of the POC VL testing platforms. Thus, we have 39 purposefully selected existing highly specialized laboratories for HIV that have pre- and post-PCR rooms, i.e., 40 NPHL, the three existing HIV VL testing labs, and a fourth referral hospital laboratory to the list of potential POC 41 DRT labs, as these facilities can maintain the technical expertise needed to run this assay. Thus, five total DRT 42 laboratories were used to model turnaround time; from here on, we refer to the NPHL as the national laboratory 43 and the other four as POC DRT hubs. We were also restricted to just one POC DRT machine prototype for this 44 modeling exercise. 45

We provide a flowchart of the POC DRT system as Supplementary Figure 1.

48 49 **2.4 DRT Rate Estimation**

Estimating the demand data for DRT has proven challenging due to the structure of publicly accessible routine
data and the difficulties associated with using individual-level data, including issues with patient identity tracking.
In addition, missing data and inconsistencies were observed to varying degrees depending on the
characteristic.(37) As a result, there are no established standards in the literature for such estimations at the
country level or within smaller geographic areas.(38) It is necessary to use estimated proportion of receiving
DRT among people living with HIV to approximate the DRT demand.

- 57
- 58 59

BMJ Open

To incorporate a range of possibilities for the demand of DRT, we considered the following two scenarios based on the overall Kenya MoH HIV treatment guidelines (Figure 1).(35) For Scenario 1, we model the current DRT demand based on existing data on high VLs from the available data for Kisumu County from the Kenya MoH HIV VL dashboard.(39) We propose a range of demand values that includes an upper estimate based on the assumption of perfect adherence to the 2022 Kenyan guidelines. This approach is motivated by the observation that the current demand for DRT may underestimate the true need for the service. In the figure, the blocks colored blue represent the chain leading to DRT, with the green blocks showing variable rates. We computed the DRT proportion with combinations of the two varying parameters of (1) percentage of the second VL being conducted (range 25-100%) and (2) the 2nd VL being >1000 copies/ml (range 25-75%). The estimated proportion of receiving DRT under Scenario 1 ranges from 0.40% to 4.80%. Details of the calculation process 10 can be found in Supplementary Table 2. For Scenario 2, we consider a more idealized case scenario where DRT 11 is recommended earlier in algorithm management, and therefore, chose a lower VL level and earlier step in VL 12 monitoring to conduct DRT, akin to high-income country settings, where DRT is done at first detection of viremia 13 (e.g., DRT requested at 1st VL >200 copies/ml). This scenario has no variable rates. Of note, while the most 14 15 recent Kenya MoH HIV treatment guidelines generally recommend using a VL cutoff threshold of >200 copies/ml 16 as non-suppression, unfortunately, estimates of DRT demand are only available for VL as low as 400 copies/ml. 17 The estimated proportion of receiving DRT under Scenario 2 is 14.62%. 18

2.5 Data Acquisition

1

2

3

4

5

6

7

8

9

19

20

21 Our team collected model parameter information through collaboration with Kenyan policymakers and laboratory 22 specialists. **Table 1** lists all model parameters we used in the model, base case values, and their data sources. 23 Note that in the table, we considered two scenarios of DRT rate. The operational parameters that can be varied 24 for sensitivity analysis include transportation and batching parameters, queueing parameters in national 25 laboratory and POC DRT hubs. As a base case, we assumed that samples are sent once a week to the national 26 laboratory and daily to other POC DRT hubs by each facility, using motorbikes as the transportation mode, under 27 average road and weather conditions. 28

29 2.6 Model: Optimization and Queueing Model 30

31 This section outlines the formulation of our optimization model, including decision variables, constraints, and 32 objectives. The primary goal of the model is to improve the total turnaround time of the whole testing system by 33 reorganizing the referral network. Further information about the mathematical expressions used in the model can 34 35 be found in the Part 3 of Supplementary materials. 36

37 The decision variable is a binary referral indicator (i.e., 0 or 1) which connects each facility with testing demand 38 and a potential service site. If their referral indicator is equal to 1, it means the corresponding facility sends their 39 testing samples to that service site. Two constraints are considered for both demand and supply sides. For the 40 demand side, there is one constraint ensuring that each testing demand is met, and the samples are assigned 41 to only one testing facility. For the supply side, the total number of accepted samples for the national laboratory 42 and POC DRT hubs should not exceed its capacity. 43

44 The objective of the model is to minimize the overall time it takes to process the DR testing samples across all 45 146 facilities. This time is made up of three parts: the time it takes for a facility to prepare and send the samples 46 (batching delay), the time it takes for the samples to be transported to the testing site (transportation time), and 47 the time it takes for the samples to be processed at the testing site (processing time). 48

49 The processing time in the DRT laboratories was analyzed using queueing models, which are used to represent 50 systems that involve waiting lines. The M/M/s gueueing model, one of the most widely studied models, was used 51 to model the arrival and processing of DRT samples at each selected laboratory.(40) Two separate gueues were 52 built to reflect the processes: entering samples into the computer system and sample preparation and testing 53 54 process. The processing time in the system is the sum of these two queueing times.

56 For practical use, we focused on optimizing two factors - batching delay time and transportation time - in the 57 objective function. Since we do not optimize over processing time, we have introduced a pre-determined and 58

59 60

2

3 4

5

6

7

8

9

BMJ Open

adjustable maximum utilization rate to avoid excessively large service times. Layout of Excel Decision Support Tool can be found in Supplementary Figure 2 and details can be found in Part 4 of Supplementary materials. **3.0 RESULTS**

In the results section, we compare two networks: the first solely comprises the national laboratory, and the second incorporates four POC DRT hubs alongside the national laboratory. Both networks were evaluated against two DRT rate scenarios—scenario 1 with rates ranging from 0.4% to 4.8%, and scenario 2 with a fixed rate of 14.62%. We report the mean turnaround time for each scenario under optimized network conditions. The maximum utilization rate is heuristically set at 0.9 for the national laboratory and 0.7 for the hub.

The section is further organized as follows: Section 3.1 provides a statistical summary of the performance of the system in turnaround time under varying DRT rates (scenario parameter); in section 3.2, we visualize the facilities and referral networks on a map; and section 3.3 focuses on the sensitivity analyses for several key operational parameters.

16 **3.1 Turnaround Time**17

18 Under the national-laboratory-only network, when DRT rate ranges from 0.4% to 1.2%, the mean turnaround 19 time across all 146 facilities is about 9 working days, which is consistent with the current observed turnaround 20 time (per unpublished, internal data from NPHL). However, as the DRT rate increases and reaches 1.6%, 21 demand exceeds capacity and waiting times become excessively long, rendering the model infeasible. By 22 contrast, when the 4 POC DRT hubs are added to the network, the mean turnaround time reduces to between 23 1.13 and 2.11 working days, substantially improving system efficiency. The POC DRT hubs network remains 24 feasible until the DRT rate reaches 4.8%, at which point the addition of more POC machines or improvements 25 to the capacity of the national laboratory would be needed to meet the DRT demand. Of note, our results show 26 that as the DRT rate increases, the mean turnaround time exhibits a monotonically increasing trend for both 27 networks. In the POC DRT hubs model, when POC DRT hub capacity is insufficient to meet demand, samples 28 are re-routed to national laboratory. As presented in **Table 2**, the increase in the DRT rate to 2.4% is associated 29 with a marked surge in the standard deviation of turnaround time from 0.05 to 0.87 working days, as well as an 30 escalation in the maximum of turnaround time from 1.71 to 8.56 working days. 31

3233 3.2 Referral Network Maps

34 35 We present a visualization of the referral network, highlighting both national laboratory and POC DRT hubs in 36 Figure 2. The visualizations are organized into different levels of DRT rate (0.4%, 1.2%, 3.6%), each with one 37 plot displaying the complete map encompassing all facilities in Kisumu County. When DRT rate is 3.6%, we 38 provide an additional plot zooming into facilities surrounding Kisumu city to reflect the involvement of the national 39 lab when DRT rate grows. The figure does not contain a panel showing the national-laboratory-only network, 40 since all samples are directed to that laboratory. Typically, facilities forward samples to the POC DRT hub closest 41 to their location, with exceptions arising due to limited capacity at the nearest testing hub. At DRT rates of 0.4% 42 and 1.2%, the referral network is similar, with demand for DRT largely being handled by three POC DRT hubs 43 (KEMRI CDC HIV/R Laboratory, KEMRI/Walter Reed CRC Laboratory, and JOOTRH). At these two levels of 44 DRT rate, the AMPATH Care Laboratory and the national laboratory do not receive any samples from Kisumu 45 County, presumably due to high transportation times. When the DRT rate increases to 3.6%, the referral network 46 expands to incorporate both the AMPATH Care Laboratory and the national laboratory. More specifically, when 47 the DRT demand proportion ranges from 0.4% to 1.6%, no facilities send samples to the national lab. However, 48 when the proportions are 2.4%, 3.2%, and 3.6%, 2, 6, and 9 facilities out of 146, respectively, send samples to 49 the national lab. Those facilities sending their samples to NPHL face substantially longer turnaround times due 50 to the extended transportation and batching times. 51

52 53 **3.3 One-Way Sensitivity Analyses**54

Table 3 outlines the mean turnaround time of all facilities under three different settings for each parameter, as well as their percentage change compared with the base case results. We ground these changes at a DRT rate of 1.2% with the national-laboratory only model, 1.2% with adding four POC DRT hubs model, and 3.6% with the latter model. For quick visualization, a gray scale captures the magnitude of change from base case.

1 We further conducted one-way sensitivity analyses on key operational parameters. Our goal was to perform 2 these analyses using both the national-laboratory-only model and the optimized model with POC hubs, selecting 3 different DRT rates that are feasible. Batching delay mode had the most substantial impact on the mean 4 turnaround time in the national-laboratory-only network. Specifically, when transitioning from a weekly to a twice-5 a-week or daily batching delay mode, the mean turnaround time decreased by 34.3% or 80.1%, respectively. In 6 both the national laboratory and POC DRT hubs networks, we observed that adding POC DRT machines or 7 improving the service rate also improved the system's efficiency. For example, the addition of two machines for 8 all existing hubs led to a 40.8% reduction in turnaround time. On the other hand, increasing the operational 9 capacity of national laboratory had a minor impact on the mean turnaround time under all settings, suggesting 10 that expanding the capacity of the national laboratory (e.g., by adding more machines or human resources) 11 would not substantially improve the system's efficiency. In addition, road and weather conditions had negligible 12 effects on the mean turnaround time in all scenarios, while transportation mode had a more substantial impact 13 on the turnaround time, particularly with walking sample delivery—an unlikely scenario—compared to a base 14 case of motorbike transport (93.5% slower). However, car transport was not meaningfully better (only 2.7% 15 16 faster) compared to motorbike transport. 17

4.0 DISCUSSION

18

19

20 Our modeling study, employing systems engineering methodologies, reveals that POC DRT is likely to be 21 required in addition to centralized laboratory testing to realize the demand for DRT in LMICs in the upcoming 22 years. The existing strategy, in which a solitary national laboratory is responsible for conducting DRT for the 23 entire laboratory network, will rapidly encounter capacity limitations if the DRT demand were to merely triple from 24 0.4% to 1.2%. The new configuration of a POC DRT network is designed to accommodate up to a ninefold 25 escalation in the current rate, from 0.4% to 3.6%. As noted previously, despite marked enthusiasm for 26 dolutegravir-containing regimen use in LMICs, DR will be an enduring concern. DR to dolutegravir is already 27 emerging, (9,41–45) and because it remains unclear what regimens should be utilized in cases of dolutegravir 28 resistance, the use of DRT is only going to increase as surveillance for dolutegravir resistance intensifies in 29 LMICs. Though the maximum potential DRT demand rate (14.6%) modeled in our Scenario 2 is highly 30 improbable to occur in LMICs in the foreseeable future, there is a pressing need for a substantial increase in 31 centralized and POC DRT capacity to cope with the likely upsurge in DRT demand. This increase in capacity will 32 be critical to ensuring that LMICs are able to effectively manage the growing need for HIV DR test especially 33 among the children and pregnant women living with HIV that are more sensitive to return of results. 34 35

36 One of the largest determinants of turnaround time was the batching delay. For instance, increasing the sample 37 transportation frequency from a weekly to a twice-weekly basis could potentially halve the turnaround time. 38 Furthermore, if samples were transported daily, the turnaround time could be halved once again, potentially 39 resulting in more efficient and timely processing of samples. Of course, a trade-off between the cost and labor 40 of frequent shipment against economies of scale of batching need to be considered when determining the 41 batching delay for transport of samples from a spoke to a hub facility. By having closer POC DRT facilities to the 42 spoke facilities than the national laboratory, this issue of batching delay is overcome by a network that includes 43 POC DRT hubs. Since direct data about the impact of POC DRT testing on results utilization has not been 44 studied, parallels with POC VL testing may be useful: although POC VL testing has not necessarily consistently 45 improved viral suppression, (46–48,21) improved turnaround times are highly motivating for providers and 46 patients(49) and results utilization appears to improve as well.(20,47,50) 47

48

Another important factor influencing turnaround time is the service rate or operational capacity of POC machines. 49 This expansion of POC machines may lead to very efficient and timely delivery of test results (possibly within 50 one day). However, our study suggests that augmenting the operational capacity of the national laboratory does 51 not have a substantial impact on reducing the mean turnaround time for DRT. This is because facilities continue 52 to experience substantial delays due to the long transport and batching delays involved in sending samples to 53 the national laboratory. Furthermore, since the national laboratory has a limited capacity share reserved for 54 55 Kisumu County to process samples from other parts of the country, it is fundamentally limited in improving 56 turnaround times for the region. While we did not explicitly model the additive improvements in both increasing 57 the operational capacity at the centralized laboratory and reducing the batching delays, were those factors more 58 easily modifiable for a given national laboratory, it is possible that a national laboratory network could be 59

2

3

BMJ Open

responsive to the increasing needs of increasing DRT demand over time. Therefore, decision-makers should consider focusing on optimizing POC machine capacity as a potentially more effective approach to improve the overall performance of the DRT network.

4 Given our findings, we suggest that decision makers should prioritize the introduction of POC DRT machines to 5 meet the current and anticipated demand for DRT in Kisumu County.(51) This would effectively reduce the 6 turnaround time and offer several programmatic advantages. POC has been shown to increase patient 7 satisfaction and adherence, (52) reducing healthcare costs by minimizing multiple clinic visits for result 8 inquiries(53). Implementing POC DRT hubs may address access disparities for marginalized communities facing 9 limited investments, as we have shown with POC VL hubs[3].(31) It also ensures proper chain of custody, 10 mitigating specimen rejection and errors in centralized referral networks. (54,55) Onsite POC testing significantly 11 reduces the risk of poor results, enhancing clinical follow-up and confidence in laboratory systems. Additionally, 12 it may be beneficial for decision makers to explore the possibility of improving the frequency of batching samples 13 to the national laboratory and substantially increasing the service rate of POC machines as potential next steps 14 to further enhance the system's paerformance. 15

16

33

35

17 Despite unique insights yielded by our model, there are several limitations to this work. First, one of the biggest 18 challenges in selecting POC DRT hubs for DRT is the intrinsic laboratory capacity for that hub to handle the 19 more technical elements related to HIV DR vs. VL testing. This immediately limits the pool of candidate hubs to 20 a few select facilities already functioning at a relatively high laboratory capacity. Second, the model utilizes VL 21 demand data from 2019, as more recent data may be affected by COVID-19-related VL testing reagent shortages. 22 Third, we emphasize only time delays; however, the budget of machine installment, staff training and 23 development programs have not been considered in this model, necessitating a further cost-effectiveness 24 analysis. Fourth, future models could model clinical decision-making parameters, such as results utilization, to 25 better demonstrate utility of such models. Fifth, this model is limited to the service delivery level of Kisumu County 26 and would require expansion for it to be applicable in other counties. Finally, our formative work was limited to 27 two focus groups with 12 total participants. On face value, this may have failed to reach thematic saturation or 28 identify other model inputs or attributes that were desirable to decision-makers. However, the source population 29 of individuals who make the types of resource allocation decisions targeted by this model is reasonably small. 30 We elected to have a smaller sample size that included individuals whose scope of work is directly related to the 31 model question. 32

34 5.0 CONCLUSIONS

In conclusion, our findings provide a valuable framework for improving the current DRT laboratory network system in Kenya, offering decision makers an opportunity to identify ways forward for DRT demand estimation, optimal referral networks and identifying key factors like transportation delays and operational capacity of POC DRT hubs. As the demand for DRT is expected to increase, we recommend the inclusion of POC DRT hubs to handle a larger volume of samples within an acceptable turnaround time.

Table 1: Model parameters, assumptions, and data sources.

Parameter	Base Case Value	Note
HIV VL test demand (per working	ı day)	
HIV VL Testing demand in 146 facilities	Ranges from 0 to 37 (per working day) for different facilities	The quantity of VL samples from each facility is determined through the HIV client volume data from 2019 in Kisumu County's DHIS II. This was necessary because of the COVID-19 pandemic-related interruptions in 2020 and the subsequent nationwide interruptions in VL testing. Details of these estimations can be found in our related work on HIV VL testing.(31)
DRT rate		Data Source: http://kmhfl.health.go.ke/ and https://dhis2.org/
DRITALE		
Scenario 1	0.40%~4.80%	Proportion of valid VL tests unsuppressed at VL≥1000 copies/m threshold * Percentage completing second VL testing * Percentage of second VL≥1000 copies/ml. Calculation process with parameter combinations can be found in Supplementary Table 2 and details of the data source can be found in Supplementary Table 3.
		Data Source: https://viralload.nascop.org/
Scenario 2	14.62%	Proportion of valid VL tests unsuppressed at VL≥ 200 copies/m threshold. Of note, we changed the threshold from newly recommended 200 to 400 copies/ml since the data provided does no enumerate values at the 200 copies/ml threshold.(35)
HIV DR test demand (per working	g day)	
under Scenario 1	Minimum demand is 0; maximum demand ranges from 0 to 2	HIV VL test demand * DRT rate
HIV DRT demand in 146 facilities under Scenario 2	Ranges from 0 to 5	4.
Transportation		
Distance between all facilities to the national laboratory and POC DRT hubs (km)	0 to 370	We used Google Map API to collect the distance and time data give the name of facilities in Kisumu, Kenya and the locations of the national laboratory and hubs. (https://developers.google.com/maps)
Speed: (km/hour)	5 (walk), 20 (bike), 40 (motorbike), 50 (car)	To calculate the transportation time, we provided different types of transportation modes and allowed the user to decide which one to us and estimated the average speed for each transportation mode.
Road condition adjustment coefficient	0.8 (good), 1 (average), 1.2 (bad)	We considered different weather and road conditions and allowe users to change these conditions based on their needs. The weather and road conditions are 'good', 'average' or 'bad', and the time neede
Weather condition adjustment coefficient	0.8 (good), 1 (average), 1.2 (bad)	for transportation could be less given better weather and roa conditions.
Batching delay (min): [frequency	with which samples are	transported to testing facility (hub or national laboratory)]
Immediately	0	If the samples are sent immediately once received at the facility due t
Daily*	210	the scarcity of the demand, we would simply remove the aspect of batching.
Twice a week	1860	We assumed that each working day has 7 hours. If the samples an sent daily, the average delay time is half of the working day, which
Once a week**	3090	3.5 (hours), i.e., 210 minutes. If the samples are sent twice a week, th average delay is a whole day and a working day, which is 24+7 = 3 hours, i.e., 1860 minutes. If the samples are sent only once a week the average delay is half of 4 whole days and a working day, which (24*4+7)/2=51.5 hours, i.e., 3090 minutes. As a base case, we assume that the samples are sent daily to DRT hubs and once a week to the samples are sent to be average to the samples are sent daily to DRT hubs and once a week to the samples are sent daily to DRT hubs and a work are sent daily to DRT hubs are sent daily

Page 13 of 34

		national laboratory.
National laboratory (NPHL) queu	leing parameters	
Entering process		
Mean service rate (test per day)	100	Mean service rate refers to the average number of DR sa
Number of servers	2	 received at one central laboratory given current staffing and pristeps. Number of servers refers to the number of workers proceive the entering of samples. We assume that there are two workers in each central laboratory working on entering the samples into the system.
Machine process	•	
Mean service rate (test per day)	100	We assume each central laboratory can handle up to 500 sampl week, which in turns to be 100 samples per working day. Esti based on personal communication with central laboratory man Users can adjust the service rate to account for machine down due to maintenance, failure, etc.
Number of machines at each central lab	1	Estimates based on personal communication with central labor managers.
Percentage of capacity for DRT	100%	It is possible that a POC DRT assay could be used as a multi-d or multi-diagnostic tool, such as those that exist for HI tuberculosis, and other infectious disease testing (e.g., Gene platforms). While set at 100%, the percentage allocation of serv HIV DRT vs. another disease or diagnostic use can be modified
Percentage of DRT samples from Kisumu	7.9%	For 2021, 89 of 1123 DRT samples (7.925%) were from K County per personal communication with central laboratory man
	•	
POC DRT hub queueing parame	ters	
POC DRT hub queueing parameter Entering process	ters	4
	ters	
Entering process	[received at DRT hubs given current staffing and process steps.
Entering process Mean service rate (test per day)	100	 received at DRT hubs given current staffing and process steps. We assume that there is only one worker in each hub working of
Entering process Mean service rate (test per day) Number of servers	100	received at DRT hubs given current staffing and process steps. We assume that there is only one worker in each hub working of entering the samples into the system.
Entering process Mean service rate (test per day) Number of servers Machine process	100	Data source: personal communication with implementing p director for HIV programs in Kisumu County. OLA DR assay ca
Entering process Mean service rate (test per day) Number of servers Machine process Mean service rate (tests per day)	100	 received at DRT hubs given current staffing and process steps. We assume that there is only one worker in each hub working centering the samples into the system. Data source: personal communication with implementing performation director for HIV programs in Kisumu County. OLA DR assay can do two samples per working day. Number of servers refers to the number of POC DRT machines
Entering process Mean service rate (test per day) Number of servers Machine process Mean service rate (tests per day) Number of servers	100 1 2	 received at DRT hubs given current staffing and process steps. We assume that there is only one worker in each hub working centering the samples into the system. Data source: personal communication with implementing performance director for HIV programs in Kisumu County. OLA DR assay can do two samples per working day.
Entering process Mean service rate (test per day) Number of servers Machine process Mean service rate (tests per day) Number of servers Hub 1: KEMRI CDC	100 1 2 2	 received at DRT hubs given current staffing and process steps. We assume that there is only one worker in each hub working centering the samples into the system. Data source: personal communication with implementing performation director for HIV programs in Kisumu County. OLA DR assay can do two samples per working day. Number of servers refers to the number of POC DRT machines
Entering process Mean service rate (test per day) Number of servers Machine process Mean service rate (tests per day) Number of servers Hub 1: KEMRI CDC Hub 2: AMPATH	100 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	 received at DRT hubs given current staffing and process steps. We assume that there is only one worker in each hub working centering the samples into the system. Data source: personal communication with implementing performation director for HIV programs in Kisumu County. OLA DR assay can do two samples per working day. Number of servers refers to the number of POC DRT machines
Entering process Mean service rate (test per day) Number of servers Machine process Mean service rate (tests per day) Number of servers Hub 1: KEMRI CDC Hub 2: AMPATH Hub 3: Walter Reed CDC	100 1 2	 received at DRT hubs given current staffing and process steps. We assume that there is only one worker in each hub working centering the samples into the system. Data source: personal communication with implementing performation director for HIV programs in Kisumu County. OLA DR assay can do two samples per working day. Number of servers refers to the number of POC DRT machines
Entering process Mean service rate (test per day) Number of servers Machine process Mean service rate (tests per day) Number of servers Hub 1: KEMRI CDC Hub 2: AMPATH Hub 3: Walter Reed CDC Hub 4: JOORTH	100 1 2	 received at DRT hubs given current staffing and process steps. We assume that there is only one worker in each hub working centering the samples into the system. Data source: personal communication with implementing p director for HIV programs in Kisumu County. OLA DR assay ca do two samples per working day. Number of servers refers to the number of POC DRT machines assigned for each hub. Given that the POC DRT hubs conduct POC DRT, we assume that the POC DRT hubs conduct POC DRT, we assume that the POC DRT hubs conduct POC DRT, we assume that the POC DRT hubs conduct POC DRT, we assume that the POC DRT hubs conduct POC DRT, we assume that the POC DRT hubs conduct POC DRT, we assume that the POC DRT hubs conduct POC DRT, we assume that the POC DRT hubs conduct POC DRT, we assume that the POC DRT hubs conduct POC DRT, we assume that the POC DRT hubs conduct POC DRT, we assume that the POC DRT hubs conduct POC DRT, we assume that the POC DRT hubs conduct POC DRT, we assume that the POC DRT hubs conduct POC DRT.
Entering process Mean service rate (test per day) Number of servers Machine process Mean service rate (tests per day) Number of servers Hub 1: KEMRI CDC Hub 2: AMPATH Hub 3: Walter Reed CDC Hub 4: JOORTH Percentage of samples from Kisu	100 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	 received at DRT hubs given current staffing and process steps. We assume that there is only one worker in each hub working or entering the samples into the system. Data source: personal communication with implementing p director for HIV programs in Kisumu County. OLA DR assay ca do two samples per working day. Number of servers refers to the number of POC DRT machines

1 2 3	JOOTRH	100%	sequencing via consensus sequencing at the national, central laboratory. Our DRT demand estimates, and modeling parameters do not account for these few additional DRT samples that may be needed at the national, central laboratory.
4 5	* represents base case batchi	ing delay mode of send	ding samples to DRT hubs
6			nding samples to national laboratory
7			
8 9			
9 10			
11			
12			
13 14			
15			
16			
17 18			
19			
20			
21 22			
23			
24			
25 26			
27			
28			
29 30			
31			
32 33			
33 34			
35			
36 37			
38			
39			
40 41			
42			
43			
44 45			
46			
47			
48 49			
50			
51			
52 53			
54			
55			
56 57			
58			
59	Eorpea	r review only - http://bmio	pen.bmj.com/site/about/guidelines.xhtml
60	For pee	rieview only - http://bmJo	pen.onj.com/site/about/guideimes.xntmi

BMJ Open

		National Lab	oratory Only	National Laborator	y & POC DRT hubs
Scenarios	DRT Proportion	Turnaround time, working days Mean (SD)	Turnaround time, working days Min, Max	Turnaround time, working days Mean (SD)	Turnaround time working days Min, Max
Scenario 1	0.4%	8.52 (0.09)	8.33, 8.70	1.13 (0.07)	1.03, 1.30
	0.8%	8.53 (0.09)	8.33, 8.71	1.35 (0.2)	1.04, 1.65
	1.2%	8.55 (0.09)	8.36, 8.73	1.44 (0.15)	1.16, 1.70
	1.6%	Infea	isible	1.53 (0.05)	1.46, 1.71
	2.4%	Infea	isible	1.69 (0.87)	1.48, 8.56
	3.2%	Infea	sible	1.90 (1.49)	1.48, 8.60
	3.6%	Infea	sible	2.11 (1.81)	1.49, 8.67
	4.8%	Infea	sible	Infea	asible
Scenario 2	14.62%	Infea	sible	Infea	asible

Table 2: Statistics summary of mean turnaround time for two networks under various DRT demand proportion.

Table 3: Results for one-way sensitivity analyses, with mean and standard deviation of turnaround time in working days, and the percentage change from the base case parameter.

	National-laboratory-only (DRT rate: 1.2%)	National laboratory & POC DRT hubs (DRT rate: 1.2%)	National laboratory & POC DRT hubs (DRT rate: 3.6%)
Capacity Improvement		•	•
Improving operation capacity o	f the national lab		
current service rate *	8.55 (0.09)	1.44 (0.15)	2.11 (1.81)
1.5 times current service rate	8.52 (0.09), -0.4%	1.44 (0.15), 0.0%	2.07 (1.81), -1.9%
2 times current service rate	8.52 (0.09), -0.4%	1.44 (0.15), 0.0%	2.07 (1.80), -1.9%
Add POC DRT machines in hub	S		·
No additional machines *	**	1.44 (0.15)	2.11 (1.81)
Add 1 server for all existing hubs	**	1.23 (0.12), -14.6%	1.47 (0.90), -30.3%
Add 2 servers for all existing hubs	**	1.12 (0.07), -22.2%	1.25 (0.05), -40.8%
Improving operation capacity o	fhubs	•	
current service rate*	**	1.44 (0.15)	2.11 (1.81)
2 times current service rate	**	0.90 (0.07), -37.5%	1.06 (0.05), -49.8%
4 times current service rate	**	0.73 (0.06), -49.3%	0.79 (0.08), -62.6%
Batching delay of sending sample	es to the national lab	0	·
Daily	1.70 (0.09), -80.1%	1.44 (0.15), 0.0%	1.61 (0.11), -23.7%
Twice a week	5.62 (0.09), -34.3%	1.44 (0.15), 0.0%	1.89 (1.06), -10.4%
Once a week*	8.55 (0.09)	1.44 (0.15)	2.11 (1.81)
Transportation parameters		7	
Road/weather condition		0	
Good	8.32 (0.07), -2.7%	1.43 (0.15), -0.7%	2.06 (1.76), -2.4%
Average *	8.55 (0.09)	1.44 (0.15)	2.11 (1.81)
Bad	8.78 (0.11), 2.7%	1.46 (0.15), 1.4%	2.13 (1.87), 0.9%
Transportation mode			÷
Walk	16.54 (0.73), 93.5%	2.04 (0.48), 41.7%	3.38 (3.73), 60.2%
Bike	9.69 (0.18), 13.3%	1.53 (0.17), 6.3%	2.29 (2.08), 8.5%
Motorbike *	8.55 (0.09)	1.44 (0.15)	2.11 (1.81)
Car	8.32 (0.07), -2.7%	1.43 (0.15), -0.7%	2.06 (1.76), -2.4%

Gray Scale Scale (working days) 0~2

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

e 17 of 34	BMJ Open	
	2~4	
	4~6	
	6~8	
	8~10	
	<u>≥</u> 10	
	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

BMJ Open

Acknowledgements

1

2

3

4

5 6

24

39 40

46

60

We thank the stakeholders who participated in focus groups and advised our study team on this modeling project.

We thank the National Public Health Laboratory, National AIDS and STI Control Program (NASCOP), Kisumu County Health Management Team, Ministry of Health, and teams who provided guidance on appropriate parameters and data sources for this work.

Sex and/or Gender Data Disaggregation

7 We have not pursued sex and/or gender data disaggregation for the modeling work, as none of the modeling 8 parameters are contingent on sex and/or gender. 9

10 Author Reflexivity Statement 11

- Has the research team engaged constructively with the reflexivity statement? [Yes.] 12
- 13 Have the research partners co-developed the research study? [Yes.]
- 14 Does the study address priority research questions for the LMIC partner(s)? [Yes.]
- 15 Is there a LMIC partner who is the first or last author? If not, what is the explanation? [Yes.] 16
- How have LMIC early career researchers been incorporated as authors? [Yes, one of the first co-authors is a 17
- LMIC partner, who was instrumental in conceptualization, data procurement, and decision to submit manuscript 18 19 (see more below).]
- 20 How are data shared with LMIC partners to address research needs? [The data are from LMIC settings, and the 21
- model itself is shared with LMIC partners for decision-making in LMIC settings.] 22
- Is there open access funding to improve publication dissemination? [Yes.] 23

25 **Contributorship Statement**

26 We confirm that all authors meet the ICMJE authorship criteria. Y.W. and L.K. contributed equally to this work, 27 with R.C.P. and L.K. spearheading the conceptualization, and L.K. also managing data procurement and 28 provision. Data procurement was supported by N.Y., S.A.H., and P.O. Funding acquisition was secured by 29 R.C.P. and A.D.W. (MPI). Methodological framework was developed by Y.W., S.L., A.D.W., and R.C.P., with 30 model building and software programming being the sole responsibility of Y.W. Supervision was provided by S.L. 31 and R.C.P., while Y.W. took charge of visualization. Overall project management and regulatory compliance 32 were supported by S.A.H., with the same on the Kenyan side managed by P.O. The original draft was written by 33 Y.W. and R.C.P., with all coauthors contributing to the review and editing process. The decision to submit the 34 manuscript was made by Y.W., L.K., and R.C.P., highlighting a collaborative effort across all stages of the work. 35

36 Funding

37 This work received financial support from the National Institute of Health grant R21MH122361. 38

41 Data availability statement: De-identified data underlying this article can be made available upon reasonable 42 request to the corresponding author. 43

44 Competing Interest Statement: None declared 45

Ethical Approval Statement: We obtained ethical approval from African Medical and Research Foundation 47 48 (AMREF) (AMREF- ESRC P545/2018) and Jaramogi Oginga Odinga Teaching and Referral Hospital 49 (JOOTRH) Institutional Review Boards (IRBs) in Kenya (IERC/JOOTRH/126/19). All study procedures were in 50 line with the Declaration of Helsinki. 51

3

4

5

6 7

8

9

18

47

58 59

60

REFERENCES

- Boender TS et al. Long-term Virological Outcomes of First-Line Antiretroviral Therapy for HIV-1 in Lowand Middle-Income Countries: A Systematic Review and Meta-analysis." Clinical infectious diseases : an official publication of the. *Infect Dis Soc Am Vol* 619 2015 1453-61 Doi101093cidciv556. Published online 2015.
- 2. Turkova A; et al. Dolutegravir as first- or second-line treatment for HIV-1 infection in children. N Engl J Med 2021 Dec 30 3852531 Httpsdoiorg101056NEJMoa2108793. Published online 2021.
- 3. UNAIDS. In Danger: UNAIDS Global AIDS Update 2022. Geneva, Switzerland 2022.
- Boerma RS, Boender TS, Bussink AP, et al. Suboptimal Viral Suppression Rates Among HIV-Infected Children in Low- and Middle-Income Countries: A Meta-analysis. *Clin Infect Dis Off Publ Infect Dis Soc Am*. 2016;63(12):1645-1654. doi:10.1093/cid/ciw645
- 16 17 5. UNAIDS. Understanding Fast-Track: Accelerating Action to End the AIDS Epidemic by 2030.; 2021.
- UNITAID_HIV_Nov_2015_Dx_Landscape-1.pdf. Accessed May 11, 2023.
 http://www.unitaid.org/assets/UNITAID_HIV_Nov_2015_Dx_Landscape-1.pdf
- Scallon AJ, Hassan SA, Qian SR, et al. "I feel drug resistance testing allowed us to make an informed decision": qualitative insights on the role of HIV drug resistance mutation testing among children and pregnant women living with HIV in western Kenya. *BMC Health Serv Res.* 2023;23(1):908. doi:10.1186/s12913-023-09804-x
- 8. Global action plan on HIV drug resistance 2017–2021. Accessed March 27, 2023. https://www.who.int/publications/i/item/978-92-4-151284-8
- Paton NI MJ. Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial. *Lancet HIV 202296e381-E393*. Published online 2022.
- 10. Paton NI, Musaazi J, Kityo C, et al. Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV. *N Engl J Med*. 2021;385(4):330-341. doi:10.1056/NEJMoa2101609
- 11. Kouamou V, Inzaule S, Manasa J. Dolutegravir drug-resistance monitoring in Africa. *Lancet HIV*.
 2021;8(11):e664-e666. doi:10.1016/S2352-3018(21)00268-X
- 41
 42
 43
 43
 43
 43
 43
 43
 43
 43
 43
 43
 44
 44
 45
 45
 45
 46
 46
 46
 47
 47
 48
 48
 49
 49
 49
 49
 49
 49
 40
 41
 41
 41
 41
 41
 42
 43
 44
 45
 45
 46
 47
 47
 47
 48
 48
 49
 49
 49
 49
 49
 49
 40
 40
 41
 41
 41
 41
 41
 42
 43
 44
 44
 45
 46
 46
 47
 47
 48
 49
 49
 49
 49
 49
 49
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 40
 <
- 44
 45
 46
 47
 48
 49
 49
 49
 49
 40
 41
 41
 42
 43
 44
 44
 45
 46
 46
 47
 48
 49
 49
 49
 49
 40
 41
 41
 42
 43
 44
 44
 44
 45
 46
 47
 47
 48
 49
 49
 49
 49
 49
 40
 41
 41
 42
 44
 44
 44
 44
 45
 44
 45
 45
 46
 47
 47
 48
 49
 49
 49
 49
 49
 49
 49
 49
 49
 40
 40
 41
 41
 42
 42
 44
 44
 45
 44
 45
 44
 45
 44
 45
 44
 45
 44
 45
 45
 46
 47
 47
 48
 48
 49
 49
 49
 49
 49
 49
 49
 49
 49
 49
 49
 40
 40
 41
 41
 41
 41
 41
 42
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 45
 4
- 14. Chua RJ, Capiña R, Ji H. Point-of-Care Tests for HIV Drug Resistance Monitoring: Advances and
 Potentials. *Pathogens*. 2022;11(7):724. doi:10.3390/pathogens11070724
- ⁵¹ 15. Panpradist N BI. OLA-Simple: A software-guided HIV-1 drug resistance test for low-resource laboratories.
 ⁵² *EBioMedicine 2019 Dec5034-44 Doi 101016jebiom201911002 Epub 2019 Nov 22 PMID 31767540 PMCID* ⁵³ *PMC6921160*. Published online 2019.
- Panpradist N, Beck IA, Ruth PS, et al. Near point-of-care, point-mutation test to detect drug resistance in HIV-1: a validation study in a Mexican cohort. *AIDS*. 2020;34(9).

BMJ Open

17. Vrana JD, Panpradist N, Higa N, et al. Implementation of an interactive mobile application to pilot a rapid assay to detect HIV drug resistance mutations in Kenya. *PLOS Glob Public Health*. 2022;2(2):e0000185. doi:10.1371/journal.pgph.0000185

1

2

3 4

5

6

7 8

9

10 11

12

13

14

46

58 59

- Pham MD, Nguyen HV, Anderson D, Crowe S, Luchters S. Viral load monitoring for people living with HIV in the era of test and treat: progress made and challenges ahead - a systematic review. BMC Public Health. 2022;22(1):1203. doi:10.1186/s12889-022-13504-2
- 19. Pai N. Barriers to Implementation of Rapid and Point-of-Care Tests for Human Immunodeficiency Virus Infection: *Find Syst Rev* 1996-2014 *Point Care* 143 81-87. Published online 2015.
- Drain PK. Point-of-care HIV viral load testing combined with task shifting to improve treatment outcomes (STREAM): findings from an open-label, non-inferiority, randomised controlled trial. Lancet HIV 74 E229-E237. Published online 2020.
- Patel RC, Oyaro P, Thomas KK, et al. Point-of-care HIV viral load and targeted drug resistance mutation
 testing versus standard care for Kenyan children on antiretroviral therapy (Opt4Kids): an open-label,
 randomised controlled trial. *Lancet Child Adolesc Health*. Published online August 17, 2022.
 doi:10.1016/S2352-4642(22)00191-2
- 21 22. Palvannan RK, Teow KL. Queueing for healthcare. J Med Syst. 2012;36(2):541-547. doi:10.1007/s10916 22 010-9499-7
 23
- 23. Bean DM, Taylor P, Dobson RJB. A patient flow simulator for healthcare management education. *BMJ Simul Technol Enhanc Learn*. 2019;5(1):46-48. doi:10.1136/bmjstel-2017-000251
- 27
 24. Dong J, Perry O. Queueing Models for Patient-Flow Dynamics in Inpatient Wards. *Oper Res.* 2020;68(1):250-275. doi:10.1287/opre.2019.1845
- ³⁰
 ³¹
 ³²
 ³⁵
 ³⁶
 ³⁶
 ³⁷
 ³⁷
 ³⁷
 ³⁸
 ³⁹
 ³⁹
 ³⁰
 ³¹
 ³¹
 ³²
 ³¹
 ³²
 ³⁵
 ³⁵
 ³⁶
 ³⁶
 ³⁷
 ³⁶
 ³⁷
 ³⁷
 ³⁷
 ³⁸
 ³⁹
 ³⁰
 ³¹
 ³²
 ³⁵
 ³⁶
 ³⁶
 ³⁷
 ³⁷
 ³⁶
 ³⁷
 ³⁶
 ³⁷
 ³⁷
 ³⁶
 ³⁷
 ³⁷
 ³⁶
 ³⁷
 ³⁶
 ³⁷
 ³⁶
 ³⁷
 ³⁶
 ³⁷
 ³⁶
 ³⁷
 ³⁶
 ³⁷
 <li
- 26. Heching A, Hooker JN, Kimura R. A Logic-Based Benders Approach to Home Healthcare Delivery. *Transp* Sci. 2019;53(2):510-522. doi:10.1287/trsc.2018.0830
- 27. Chan TCY, Mahmood R, O'Connor DL, et al. Got (Optimal) Milk? Pooling Donations in Human Milk Banks
 with Machine Learning and Optimization. *Manuf Serv Oper Manag*. Published online November 17, 2023:msom.2022.0455. doi:10.1287/msom.2022.0455
- 28. Bertsimas D, Pauphilet J. Hospital-Wide Inpatient Flow Optimization. *Manag Sci.* Published online
 September 25, 2023:mnsc.2023.4933. doi:10.1287/mnsc.2023.4933
- 43
 44 29. Deo S, Sohoni M. Optimal Decentralization of Early Infant Diagnosis of HIV in Resource-Limited Settings.
 45 Manuf Serv Oper Manag. 2015;17(2):191-207. doi:10.1287/msom.2014.0512
- 30. Jónasson JO, Deo S, Gallien J. Improving HIV Early Infant Diagnosis Supply Chains in Sub-Saharan
 Africa: Models and Application to Mozambique. *Oper Res*. 2017;65(6):1479-1493.
- 31. Wang Y, Wagner AD, Liu S, et al. Using queueing models as a decision support tool in allocating point-of care HIV viral load testing machines in Kisumu County, Kenya. *Health Policy Plan*. 2024;39(1):44-55.
 doi:10.1093/heapol/czad111
- 32. Boeke CE, Joseph J, Wang M, et al. Point-of-care testing can achieve same-day diagnosis for infants and rapid ART initiation: results from government programmes across six African countries. *J Int AIDS Soc.* 2021;24(3):e25677. doi:10.1002/jia2.25677

BMJ Open

1 2 3	33.	Yildirim M, Webb KA, Ciaranello AL, et al. Increasing the initiation of antiretroviral therapy through optimal placement of diagnostic technologies for pediatric HIV in Zimbabwe: A modeling analysis. <i>Int J Infect Dis IJID Off Publ Int Soc Infect Dis</i> . 2023;134:31-38. doi:10.1016/j.ijid.2023.05.013
4 5 6	34.	Kenya Master Health Facility List: Find all the health facilities in Kenya. Accessed May 8, 2023. https://kmhfl.health.go.ke/#/home
7 8	35.	National AIDS & STI Control Programme (NASCOP). Kenya HIV Prevention and Treatment Guidelines.
9 10 11	36.	Target product profile for HIV drug resistance tests in low- and middle-income countries: Africa. Accessed February 12, 2024. https://www.who.int/publications-detail-redirect/9789240076662
12 13 14	37.	Mwau M, Syeunda CA, Adhiambo M, et al. Scale-up of Kenya's national HIV viral load program: Findings and lessons learned. <i>PLoS One</i> . 2018;13(1):e0190659. doi:10.1371/journal.pone.0190659
15 16 17 18 19	38.	Parkin N, Harrigan PR, Inzaule S, Bertagnolio S. Need assessment for HIV drug resistance testing and landscape of current and future technologies in low- and middle-income countries. <i>PLOS Glob Public Health</i> . 2023;3(10):e0001948. doi:10.1371/journal.pgph.0001948
19 20 21	39.	NASCOP. NASCOP Viral Load Dashboard. Accessed March 27, 2023. https://viralload.nascop.org/
22 23	40.	Hillier FS, Lieberman GJ. Introduction to Operations Research. McGraw-Hill Education; 2015.
24 25 26 27	41.	Loosli T, Hossmann S, Ingle SM, et al. HIV-1 drug resistance in people on dolutegravir-based ART: Collaborative analysis of cohort studies. <i>MedRxiv Prepr Serv Health Sci</i> . Published online April 5, 2023:2023.04.05.23288183. doi:10.1101/2023.04.05.23288183
28 29 30 31	42.	Han YS, Mesplède T, Wainberg MA. Differences among HIV-1 subtypes in drug resistance against integrase inhibitors. <i>Infect Genet Evol J Mol Epidemiol Evol Genet Infect Dis</i> . 2016;46:286-291. doi:10.1016/j.meegid.2016.06.047
32 33 34 35	43.	Brenner BG, Thomas R, Blanco JL, et al. Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors. <i>J Antimicrob Chemother</i> . 2016;71(7):1948-1953. doi:10.1093/jac/dkw071
36 37 38 39	44.	Ngoufack Jagni Semengue E, Santoro MM, Ndze VN, et al. HIV-1 integrase resistance associated mutations and the use of dolutegravir in Sub-Saharan Africa: A systematic review and meta-analysis. <i>PLOS Glob Public Health</i> . 2022;2(10):e0000826. doi:10.1371/journal.pgph.0000826
40 41 42	45.	Collier DA, Monit C, Gupta RK. The Impact of HIV-1 Drug Escape on the Global Treatment Landscape. <i>Cell Host Microbe</i> . 2019;26(1):48-60. doi:10.1016/j.chom.2019.06.010
43 44 45 46 47 48 49	46.	Fairlie L. More frequent viral load testing, with point-of-care tests has no impact on viral suppression in postpartum HIV-positive women in a randomized controlled trial in two clinics in Johannesburg, South Africa. <i>J Int AIDS Soc Vol 24 No S4 Pp 14 Gale OneFile Health Med LinkgalecomappsdocA672359364HRCAuwashmainsidgoogleScholarxidb12fecde Accessed 6 Aug 2022</i> . Published online July 2021.
50 51 52 53	47.	Chang C AO. Clinical Outcomes in a Randomized Controlled Trial Comparing Point-of-Care Versus Standard HIV Viral Load Monitoring in Nigeria. <i>Clin Infect 2022 Jul 22ciac605 Doi 101093cidciac605 Epub Ahead Print PMID 35867672</i> . Published online 2022.
54 55 56 57 58	48.	Patel RC. Impact of point-of-care HIV viral load and targeted drug resistance mutation testing on viral suppression among Kenyan children on antiretroviral therapy: Results from an open-label, randomized controlled trial (Opt4Kids). <i>Unpubl Manuscr</i> . Published online 2022.
59 60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

- 49. Qian SRW, Hassan SA, Scallon AJ, et al. "After viral load testing, I get my results so I get to know which path my life is taking me": qualitative insights on routine centralized and point-of-care viral load testing in western Kenya from the Opt4Kids and Opt4Mamas studies. *BMC Health Serv Res*. 2022;22(1):1540. doi:10.1186/s12913-022-08593-z
- 50. Jain V et al. RAPID-VL intervention improves viral load ordering, results turnaround time and viral suppression: a cluster randomized trial in HIV clinics in Uganda. *11th Int AIDS Soc Conf HIV Sci Abstr* OALD01LB03 2021. Published online 2021.
- 51. Scallon A, Hassan S, Qian SRW, et al. I feel drug resistance testing was giving us an aspect of making an informed decision": Qualitative insights on the role of HIV drug resistance mutations testing among children and pregnant women living with HIV in western Kenya. *Press*.
- 52. Lilly CM, Ensom E, Teebagy S, et al. Patient Preferences for Point-of-Care Testing: Survey Validation and Results. *Point Care*. 2020;19(4):112-115. doi:10.1097/poc.0000000000214
- 53. Lucas SM. Current & Future Applications of Point-of-Care Testing.

- 54. Katoba J, Kuupiel D, Mashamba-Thompson TP. Toward Improving Accessibility of Point-of-Care
 Diagnostic Services for Maternal and Child Health in Low- and Middle-Income Countries. *Point Care*.
 2019;18(1):17-25. doi:10.1097/POC.0000000000180
- 55. Plebani M. Does POCT reduce the risk of error in laboratory testing? *Clin Chim Acta Int J Clin Chem*.
 2009;404(1):59-64. doi:10.1016/j.cca.2009.03.014


Legend of Figures


Figure 1: Scenario 1 (current DRT based on existing VL data from 2019) and 2 (more idealized DRT) flowchart for DRT demand estimation for Kisumu County, Kenya.

Note:

- 1. Color Schematic: In both Scenarios 1 and 2, blue colored blocks are utilized to illustrate the trajectory of HIV samples that lead to DRT at the final stage, in accordance with various guidelines. In Scenario 1, green colored blocks are employed to signify the consideration of various rates for conducting a second VL test and the suppressing rate for the second VL.
 - 2. Data source: NASCOP VL database¹¹. Details of data used can be found in Supplementary Table 3.


Figure 2: Referral network when POC DRT hubs are included in the testing network, with varying DRT rates and zoom levels. The markers with colors of red and blue correspond to national and four POC DRT hubs, respectively. Additionally, blue dots are used to represent 146 facilities. The network is shown through links scied DRI Iauc. between facilities and selected DRT laboratories.





Scenario 1 (current DRT based on existing VL data from 2019) and 2 (more idealized DRT) flowchart for DRT demand estimation for Kisumu County, Kenya.

90x90mm (300 x 300 DPI)



Supplementary Materials

Part 1: Supplementary Tables and Figures

Supplementary Table 1: Demographics of FGD participants (Number of participants: 12).

Characteristic	Median (IQR) or n (%)
Age	43 (37.5, 45)
Workstation	
County MOH	11 (92%)
Implementing partner	1 (8%)
Male	8 (67%)
Highest level of education	
Bachelor's degree	6 (50%)
Master's Degree	6 (50%)
Years of education completed	20 (19, 22)
Years working with HIV treatment monitoring	10 (9,13)
Activities related to HIV treatment monitoring currently involved in:	
Managing clinical teams that order or utilize drug resistance results for patient management	11 (92%)
Managing clinical teams that order or utilize viral load results for patient management	9 (75%)
Coordinating logistical issues for HIV laboratory tests	3 (25%)
Regulatory, validation, or verification of HIV-related machines or procedures	3 (25%)
Determining budgets	2 (17%)
Ordering and interpreting viral load for patients	1 (8%)
Ordering and interpreting drug resistance tests for patients	1 (8%)
Other coordination	1 (8%)

Supplementary Table 2: DRT demand estimation with combinations of percentage of doing second VL testing and percentage of second VL ≥1000 copies/ml.

Proportion of patients receiving D	DRT Percen	tage of second VL <u>></u> 1000 cop	bies/ml
Percentage completing second VL t	cesting 25%	50%	75%
25%	0.40%	0.80%	1.20%
50%	0.80%	1.60%	2.40%
75%	1.20%	2.40%	3.60%
100%	1.60%	3.20%	4.80%

Note: Proportion of patients receiving DRT = Proportion of valid VL tests unsuppressed at VL>1000 copies/ml threshold * Percentage completing second VL testing * Percentage of second VL>1000 copies/ml.

Supplementary Table 3: Parameters for estimating the DRT rate.

Total VL tests done:	153,118		
Routine VL Tests with Valid Outcomes:	143,323	Proportion of Routine VL Tests with Valid Outcomes:	93.60%
Viral Load ≥ 1000 copies/ml:	9,168	Proportion of Tests with Viral Load \geq 1000 copies/ml:	6.40%
Viral Load < 1000 copies/ml:	134,155	Proportion of Tests with Viral Load < 1000 copies/ml:	93.60%
Viral Load < 400 copies/ml:	122,364	Proportion of Tests with Viral Load < 400 copies/ml:	85.38%

60

BMJ Open

Viral Load	401 - 999 copies/ml:	11,791	Proportion of Tests with Viral Load 401 - 999 copies/ml: 8.23%
Confirmatory	y Repeat Tests:	8,042	Proportion of Confirmatory Repeat Tests: 5.25%
Viral Load	<u>≥</u> 1000 copies/ml:	2,309	Proportion of Tests with Viral Load > 1000 copies/ml: 28.71%
Viral Load	< 1000 copies/ml:	5,733	Proportion of Tests with Viral Load < 1000 copies/ml: 71.29%
Baseline VL	S:	1,753	Proportion of Baseline VLs: 1.14%
Viral Load	<u>≥</u> 1000 copies/ml:	128	Proportion of Tests with Viral Load \geq 1000 copies/ml:7.30%
Viral Load	< 1000 copies/ml:	1,625	Proportion of Tests with Viral Load < 1000 copies/ml: 92.70%
Facilities	s receive drug	Send to	e working process of the system. point-of-care hubs with ily batching delay Conduct drug to the system Conduct drug resistence testin
resistence	testing samples		the national laboratory veekly batching delay
Panel A: USER DECISIONS There are currently 7 facilitie point of care machines in Kis		RESU	LTS
USER DECISIONS There are currently Tracille port of care machines in the send samples to NHRI. How many times a week do send samples to there cert how many times a week do send samples to there cert how many times a week do send samples to there cert how many times a week do send samples to there to and samples to the total to the total total total total button to pert Additional changes of debat transportation mode Read conditions If weather conditions If weather conditions If weather conditions If you have to the total total the model proceed to Afil Changes Table DRT RATE	umu County. as a facility al alce a meak as a facility al alce as a facility baily	s (minutes) 3000 210 210 Jan red per km (1/speed) cient 1 setficient 1	
USER DECISIONS There are currently Tracible port of care machines in the send samples to NHRI. How many times a week do send samples to NHRI. How many times a week do and samples to Hore cert How many times a week do and samples to Hore cert Hore many times a week do and samples to Hore to Hore Particulars of the Read conditions Hore and any of the table of the Hore and the sample of the table of the Hore and the sample of the table of the Hore and the sample of the table of the Hore and the same of the Hore and the sample of the table of the Hore and the sample of the table of the Hore and the sample of the table of the Hore and the same of the same of the same of the Hore and the same of the same of the same of the Hore and the same of the same of the same of the Hore and the same of the same of the same of the Hore and the same of the same of the same of the same of the Hore and the same of the same of the same of the same of the Hore and the same of the same	umu County. as a facility as a facility baiy baiy baiy baiy baiy baiy baiy bai	s (minutes) 3000 210 210 210 Jana red per km (1/speed) selficient required per km 1.5	LTS <u>Centralized lab</u> <u>Tests per dy</u> <u>Witing time at testing</u> <u>Location (minutes)</u> <u>Standal HV Reference Lab</u> <u>7 1 1 </u>
USER DECISIONS There are currently Tracities point of care machines in the and samples to NHTL. How many times a week do send samples to NHTL. How many times a week do send samples to Netroe cert how many times a week do send samples to Netroe cert how many times a week do end samples to Netroe cert how many times a week do send samples to Netroe cert but the notice high synthesis to Netro Becond, go to the table and but to go t Additional changes of delay Transportation mode Read conditions Weather conditions If you want for make advant the model, proceed to Att Changes Table DRIT RATE	unnu County. Is a facility b a facility b a facility b a facility c org/or sample c or	s (minutes) 3000 210 210 210 Jam red per km (1/speed) 1.5 cient 1 sefficient 1 required per km	LTS Technol HV Reference Lab 7 46 National HV Reference Lab 7 7 7 46 National HV Reference Lab 7 7 7 46 National HV Reference Lab 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7

The focus was on informing the DRT modeling inputs, outputs, and format, covering decision-making factors for

POC technology placement, prioritization of POC machines. We recruited policymakers from county Ministry of

Health teams, implementing partners, and laboratory leaders, and FGDs were conducted on Zoom in English by

a trained facilitator. A set of a priori suggested model inputs informed the FGD guide, based on the co-authors'

Part 2: Formative Qualitative Research

understanding of DRT systems in Kenya and engineering expertise.

Focus Group

Formative Input

1 2 3 4 5 6 7 8 9 10 11 12 13 17 19 20 21 24

In 2021, we conducted two virtual focus group discussions with 12 HIV treatment stakeholders, comprising representatives from county ministries of health and implementing partners. Participants had experience managing clinical teams that utilized VL and DRT results for patient management, coordinating laboratory logistics, and regulatory or budgetary decision-making. A detailed description of participant demographics is provided in Supplementary Table 3 (The table is also provided as Supplementary Table 2 in our VL modeling paper).

Overall, the processes and factors that would influence their decisions of where to place POC machines for DRT 22 were similar to those identified for POC machines for VL testing. Generally, the decision-making process would 23 require engagement with various stakeholders at multiple levels, from county assemblies and committees, to implementing partners, to civil society organizations. Factors that influenced participants' decisions on POC 25 machine placement for DRT included staffing volume, facility capacity and training, geographic accessibility, 26 disease prevalence, patient volume, and infrastructure, such as electricity and back-up power. When prioritizing 27 the placement of POC machines, participants considered various factors such as high-volume facilities, 28 accessibility to peripheral facilities, trained staff, and laboratory and power infrastructure. These considerations 29 were particularly important for facilities with a high proportion of adolescents and young people who were failing 30 to adhere to treatment. 31

Specifically, in reflecting on how these considerations might vary for decisions related to the placement of yetto-be developed POC DRT machines, the emphasis on the above factors shifted slightly. When considering the placement of POC DRT machines, participants emphasized the importance of large sample volumes, accessibility to other facilities and central labs, a consistent supply of reagents, and a high-level multidisciplinary team that can run and interpret drug resistance test results.

Part 3: Mathematical Formulation for Queueing and Optimization Models

Notations

38

41

- I = 146: the number of facilities collecting samples
- J = 5: the total number of all 4 selected hubs and 1 national laboratory
- d_i : the demand at *i*-th facility per working day (7 hours/day)
- λ_j^{46} : mean arrival rate for service (testing) site j
- 48 μ_j : mean service rate for service (testing) site j
- s_j : number of servers for service (testing) site *j*
- $\rho_j = \lambda_j / (s_j \mu_j)$: utilization ratio for service (testing) site *j* ($\rho_j < 1$).
- B_j : the batching delay time for service (testing) site j
 - T_{ij} : the transportation time from facility *i* to service (testing) site *j*
- W_j : the expected time in service site *j* 56

Expected waiting time in Queueing Theory

59 60

57

Page 29 of 34

 BMJ Open

M/M/s is one of the most widely studied queueing models, indicating that both the interarrival time distribution and service time distribution are Markovian (i.e., exponentially distributed). (2) Here we used a M/M/s queue to model the arrival and processing of DR testing samples at selected hubs and national laboratory. An M/M/s queueing model has the following analytical solution for the expected time spent in the system. The mathematical formula of the expected waiting time is shown below. The mean arrival rate in service site *j* is $\lambda_j = \sum_{i=1}^{I} d_i x_{ij}$. The idle probability in service site *j* can be calculated as P_{0j} , where

$$P_{0j} = \frac{1}{\sum_{n=0}^{s_j-1} \frac{(\lambda_j/\mu_j)^n}{n!} + \frac{(\lambda_j/\mu_j)^{s_j}}{s_j!} (\frac{1}{1-\rho_j})}$$

Then, in conclusion, the expected waiting time for service site (hubs or central labs) j, i.e., W_j is:

$$W_{j} = \frac{P_{0j}\lambda_{j}^{s_{j}}}{(s_{j}-1)!\,\mu_{j}^{s_{j}-1}(s_{j}\mu_{j}-\lambda_{j})^{2}} + \frac{1}{\mu_{j}}$$

Optimization Formulation

For modeling and optimizing the referral network, we let I = 146 be the number of facilities collecting samples, and J = 5 be the total number of selected hubs and national laboratory. To optimize the transportation cost and batching cost through re-arranging the referral network, we formulate the following optimization problem. The mathematical formula of the optimization model is shown below. Since we want to optimize the referral network and select additional hubs, the decision variables are x_{ij} .

 $x_{ij} = \begin{cases} 1, \text{ if } i^{th} \text{ facility sends samples to } j^{th} \text{ testing site} \\ 0, \text{ otherwise} \end{cases}$

The objective function is to minimize the total turnaround time of the system, including the total transportation time, total batching time, and total waiting time. Notice from the following objective, the total transportation time and total batching time are linear functions of the decision variables, while the waiting time is a non-linear function of the decision variables. The objective is shown by the formula below:

$$\min_{x_{ij}} \sum_{i=1}^{I} \sum_{j=1}^{J} x_{ij} T_{ij} + \sum_{i=1}^{I} \sum_{j=1}^{J} x_{ij} B_j + \sum_{i=1}^{I} \sum_{j=1}^{J} x_{ij} W_j$$

In the Excel tool, we only optimized the linear part of the objective due to computational complexities. This allows us to optimize the objective using 'Opensolver', an open-source Excel VBA add-in. Of note, in our Excel tool, we also set the maximum utilization for national laboratory as 0.9 and selected hubs as 0.7 to avoid overcrowding, which may incur extremely long wait time. In addition, we also have two constraints for the solutions. First, each facility only sends samples to one service site. Second, the total number of accepted samples in each selected site should not exceed its capacity. Mathematically, those constraints can be expressed as the following forms.

$$\sum_{j=1}^{J} x_{ij} = 1 \text{ for } i = 1, \dots, I$$
$$\sum_{j=1}^{J} x_{ij} d_i \le s_j \mu_j \text{ for } j = 1, \dots, J$$

Part 4: Excel Decision Support Tool

To provide a user-friendly interface for policymakers on mainstream computer systems, we organized the model in Excel and relied on the Opensolver add-in to solve the optimization part. According to the description on the

BMJ Open

Opensolver website (https://opensolver.org/), our Excel tool should be available for most Windows and Mac OS computers. Our Excel tool has eight different tabs, and to explore the full function of the tool, users may use 4 steps outlined here. To maximize user-friendliness focused on simplicity, clarity, and minimal opportunity to make an irrecoverable error, we created a "locked" version of the model in which users cannot manipulate any data on the second through fifth categories of tabs. The "unlocked" version is also available if users need to update user inputs.

Step 1: Parameters Input

Go to the "Basic Inputs & Model Outputs" and "Advanced Inputs Changes" tabs to change the basic and advanced parameters settings. We differentiated the two tabs of Inputs to improve the usability of the tool. Frequently changed parameters settings are incorporated into the basic tab. In addition, the main results, including expected waiting time at selected hubs and national laboratory. (Supplementary Figure 2, Panel A).

Step 2: Predetermined Parameters (Most users can skip this step)

In the "distance matrix" and 'transportation time matrix' tabs, we provide the transportation data collected from Google Map, including the distance between each facility to selected labs and the national laboratory and the estimated time for transportation. In "MIMIs" tab, we show the parameters for different queues; advanced users could change the service rate according to their local knowledge. In "MIMIs calculation" tab, the users could see the detailed calculation and main output of each queueing system.

Step 3: Solving the Model

Go to the "Programming" tab, the users could see the way we lay out the optimization model and could also rerun the model using the 'OpenSolver' package. Since only 5 referral labs are incorporated in the DR testing system, users can achieve the optimized results in seconds.

Step 4: Check results

In the "Referral Network" tab, users could find detailed information for all 146 facilities, including their names, demand data, referral testing labs to send their samples under the optimized model, the simulated expected waiting time, transportation time and total turnaround time. (Supplementary Figure 2, Panel B).

Reference:

[1] Wang Y, Wagner AD, Liu S, et al. Using queueing models as a decision support tool in allocating point-of-care HIV viral load testing machines in Kisumu County, Kenya. Health Policy Plan. 2024;39(1):44-55. doi:10.1093/heapol/czad111

[2] Introduction to Operations Research, by Frederick Hillier, 10th edition, 2014.

1 2 3 4 5 6 7 8 9 10 11 12 13	
14 15 16 17 18 19 20 21 22 23 24 25 26	
20 27 28 29 30 31 32 33 34 35 36 37	
38 39 40 41 42 43 44 45 46 47 48	
49 50 51 52 53 54 55 56 57 58 59 60	

Revised Standards for Quality Improvement Reporting Excellence (SQUIRE 2.0)	
September 15, 2015	

Text Section and Item Name	Section or Item Description	
Notes to authors	 The SQUIRE guidelines provide a framework for reporting new knowledge about how to improve healthcare The SQUIRE guidelines are intended for reports that describe system level work to improve the quality, safety, and value of healthcare, and used methods to establish that observed outcomes were due to the intervention(s). A range of approaches exists for improving healthcare. SQUIRE may be adapted for reporting any of these. Authors should consider every SQUIRE item, but it may be inappropriate or unnecessary to include every SQUIRE element in a particular manuscript. The SQUIRE Glossary contains definitions of many of the key words in SQUIRE. The Explanation and Elaboration document provides specific examples of well-written SQUIRE items, and an in-depth explanation of each item. Please cite SQUIRE when it is used to write a manuscript. 	
Title and Abstract		
1. Title	Indicate that the manuscript concerns an <u>initiative</u> to improve healthcare (broadly defined to include the quality, safety, effectiveness, patient-centeredness, timeliness, cost, efficiency, and equity of healthcare)	
2. Abstract	 a. Provide adequate information to aid in searching and indexing b. Summarize all key information from various sections of the text using the abstract format of the intended publication or a structured summary such as: background, local <u>problem</u>, methods, interventions, results, conclusions 	
Introduction	Why did you start?	
3. <u>Problem</u> <u>Description</u>	Nature and significance of the local problem	
4. Available knowledge	Summary of what is currently known about the problem, including relevant previous studies	

1	
2	
3	
4	
5	
6	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
54 55	
56	
57	
58	
59	
60	

5. Rationale Informal or formal frameworks, models, concepts, and/or theories used to explain the problem, any reasons or assumptions that were used to develop the intervention(s) and reasons why the intervention(s) was expected to work 6. Specific aims Purpose of the project and of this report Methods What did you do? 7. Context Contextual elements considered important at the outset of introducing the intervention(s) a. Description of the intervention(s) in sufficient detail that others could reproduce it b. Specifics of the team involved in the work a. Approach chosen for assessing the impact of the intervention(s) a. Approach chosen for assessing the inpact of the intervention(s) b. Approach used to establish whether the observed outcomes were due to the intervention(s). a. Measures chosen for studying processes and outcomes of the intervention(s). 10. Measures a. Measures chosen for studying processes and outcomes of the intervention(s). a. Qualitative and quantitative methods used to draw inferences. from the data b. Methods for understanding variation within the data, including the effects of time as a variable. Ethical Considerations Ethical aspects of inplementing and studying the intervention(s) and how they were addressed, including, but on timited to, formal ethics review and potential conflict(s) of interest Results What did you find? a. Initial steps of the intervention(s) and beir evolution over time (e.g., time-line di		
Methods What did you do? 7. Context Contextual elements considered important at the outset of introducing the intervention(s) 8. Intervention(s) a. Description of the intervention(s) in sufficient detail that others could reproduce it 9. Study of the Intervention(s) a. Approach chosen for assessing the impact of the intervention(s) 9. Study of the Intervention(s) a. Approach chosen for assessing the impact of the intervention(s) 10. Measures a. Measures chosen for studying processes and outcomes were due to the intervention(s), including rationale for choosing them, their operational definitions, and their validity and reliability 10. Measures a. Measures chosen for assessing completeness and accuracy of data elements that contributed to the success, failure, efficiency, and cost c. Methods employed for assessing completeness and accuracy of data 11. Analysis a. Qualitative and quantitative methods used to draw inferences from the data 12. Ethical Considerations Ehical aspects of implementing and studying the intervention(s) and how they were addressed, including, but not limited to, formal ethics review and potential conflict(s) of interest 13. Results a. Initial steps of the intervention(s) and their evolution over time (e.g., time-line diagram, flow chart, or table), including modifications made to the intervention during the project b. Details of the process measures and outcome c. Contextual elements that interacted with the intervention(s).	5. <u>Rationale</u>	explain the <u>problem</u> , any reasons or <u>assumptions</u> that were used to develop the <u>intervention(s)</u> , and reasons why the <u>intervention(s)</u> was
7. Context Contextual elements considered important at the outset of introducing the intervention(s) 8. Intervention(s) a. Description of the intervention(s) in sufficient detail that others could reproduce it 9. Study of the Intervention(s) b. Specifics of the team involved in the work a. Approach chosen for assessing the impact of the intervention(s) b. Approach used to establish whether the observed outcomes were due to the intervention(s) 10. Measures a. Measures chosen for studying processes and outcomes of the intervention(s), including rationale for choosing them, their operational definitions, and their validity and reliability 10. Measures a. Qualitative and quantitative methods used to draw inferences from the data a. Qualitative and quantitative methods used to draw inferences from the data a. Qualitative and quantitative methods used to draw inferences from the data 11. Analysis Ethical aspects of implementing and studying the intervention(s) and how they were addressed, including, but not limited to, formal ethics review and potential conflict(s) of interest Results What did you find? 13. Results a. Initial steps of the intervention(s) and their evolution over time (e.g., findure, findure, correct association between outcomes, intervention(s). 13. Results Details of the process measures and outcome a. Contextual elements b. Outpress measures and outcome b. Details of the process used as unsu	6. Specific aims	Purpose of the project and of this report
7. Context intervention(s) 8. Intervention(s) a. Description of the intervention(s) in sufficient detail that others could reproduce it 9. Study of the Intervention(s) b. Specifics of the team involved in the work a. Approach closen for assessing the impact of the intervention(s) b. Approach used to establish whether the observed outcomes were due to the intervention(s) 10. Measures a. Measures chosen for studying processes and outcomes of the intervention(s), including rationale for choosing them, their operational definitions, and their validity and reliability 10. Measures a. Measures chosen for studying processes and outcomes of the intervention(s), including rationale for choosing them, their operational definitions, and their validity and reliability b. Description of the approach to the ongoing assessment of contextual elements that contributed to the success, failure, efficiency, and cost c. Methods for understanding variation within the data, including the data 11. Analysis a. Qualitative and quantitative methods used to draw inferences from the data 12. Ethical Considerations Ethical aspects of implementing and studying the intervention(s) and how they were addressed, including, but not limited to, formal ethics review and potential conflict(s) of interest Results Initial steps of the intervention(s) and their evolution over time (e.g., time-line diagram, flow chart, or table), including modifications made to the intervention during the project b. Detais of the process measures and outcome	Methods	What did you do?
8. Intervention(s) reproduce it 9. Study of the Intervention(s) a. Approach chosen for assessing the impact of the intervention(s) b. Approach used to establish whether the observed outcomes were due to the intervention(s) b. Approach used to establish whether the observed outcomes were due to the intervention(s) 10. Measures a. Measures chosen for studying processes and outcomes of the intervention(s), including rationale for choosing them, their operational definitions, and their validity and reliability 10. Measures a. Measures chosen for studying processes, failure, efficiency, and cost c. Methods employed for assessing completeness and accuracy of data 11. Analysis a. Qualitative and quantitative methods used to draw inferences from the data 12. Ethical Considerations Ethical aspects of implementing and studying the intervention(s) and how they were addressed, including, but not limited to, formal ethics review and potential conflict(s) of interest 13. Results a. Initial steps of the intervention(s) and their evolution over time (e.g., time-line diagram, flow chart, or table), including modifications made to the intervention during the project b. Details of the process neasures and outcome c. Contextual elements c. Unintended consequences such as unexpected benefits, problems, failures, or costs associated with the intervention(s). f. Details about missing data What does it mean?	7. <u>Context</u>	
9. Study of the Intervention(s) b. Approach used to establish whether the observed outcomes were due to the intervention(s) 10. Measures a. Measures chosen for studying processes and outcomes of the intervention(s), including rationale for choosing them, their operational definitions, and their validity and reliability 10. Measures a. Measures chosen for studying processes and outcomes of the intervention(s), including rationale for choosing them, their operational definitions, and their validity and reliability 10. Measures a. Measures chosen for studying processes and outcomes of contextual elements that contributed to the success, failure, efficiency, and cost c. Methods employed for assessing completeness and accuracy of data 11. Analysis a. Qualitative and quantitative methods used to draw inferences from the data b. Methods for understanding variation within the data, including the effects of time as a variable Ethical aspects of implementing and studying the intervention(s) and how they were addressed, including, but not limited to, formal ethics review and potential conflict(s) of interest Results What did you find? a. Initial steps of the intervention(s) and their evolution over time (e.g., time-line diagram, flow chart, or table), including modifications made to the intervention during the project b. Details of the process measures and outcome Contextual elements a. Initial steps of the intervention(s). d. Observed associations between outcomes, intervention(s) d. Observed associations between outcomes, i	8. <u>Intervention(s)</u>	reproduce it
10. Measuresintervention(s), including rationale for choosing them, their operational definitions, and their validity and reliability10. MeasuresDescription of the approach to the ongoing assessment of contextual elements that contributed to the success, failure, efficiency, and cost c. Methods employed for assessing completeness and accuracy of data11. Analysisa. Qualitative and quantitative methods used to draw inferences from the data12. Ethical ConsiderationsEthical aspects of implementing and studying the intervention(s) and how they were addressed, including, but not limited to, formal ethics review and potential conflict(s) of interestResultsInitial steps of the intervention(s) and their evolution over time (e.g., time-line diagram, flow chart, or table), including modifications made to the intervention during the project13. ResultsObserved associations between outcomes, intervention(s)DiscussionWhat does it mean?ANummarya. Key findings, including relevance to the rationale and specific aims	·	b. Approach used to establish whether the observed outcomes were due
11. Analysisdata b. Methods for understanding variation within the data, including the effects of time as a variable12. Ethical ConsiderationsEthical aspects of implementing and studying the intervention(s) and how they were addressed, including, but not limited to, formal ethics review and potential conflict(s) of interestResultsWhat did you find?a. Initial steps of the intervention(s) and their evolution over time (e.g., time-line diagram, flow chart, or table), including modifications made to the intervention during the projectb. Details of the process measures and outcome c. Contextual elements that interacted with the intervention(s) d. Observed associations between outcomes, interventions, and relevant contextual elementsc. Unintended consequences such as unexpected benefits, problems, failures, or costs associated with the intervention(s). f. Details about missing dataDiscussionWhat does it mean?a. Key findings, including relevance to the rationale and specific aims	10. Measures	 <u>intervention(s)</u>, including rationale for choosing them, their operational definitions, and their validity and reliability b. Description of the approach to the ongoing assessment of contextual elements that contributed to the success, failure, efficiency, and cost
12. Ethical Considerationsthey were addressed, including, but not limited to, formal ethics review and potential conflict(s) of interestResultsWhat did you find?a. Initial steps of the intervention(s) and their evolution over time (e.g., time-line diagram, flow chart, or table), including modifications made to the intervention during the projectb. Details of the process c. Contextual elements that interacted with the intervention(s) d. Observed associations between outcomes, interventions, and relevant contextual elementse. Unintended consequences such as unexpected benefits, problems, failures, or costs associated with the intervention(s).f. Details about missing dataDiscussiona. Key findings, including relevance to the rationale and specific aims	11. Analysis	data b. Methods for understanding variation within the data, including the
13. Results a. Initial steps of the intervention(s) and their evolution over time (e.g., time-line diagram, flow chart, or table), including modifications made to the intervention during the project b. Details of the process measures and outcome c. Contextual elements that interacted with the intervention(s) d. Observed associations between outcomes, interventions, and relevant contextual elements e. Unintended consequences such as unexpected benefits, problems, failures, or costs associated with the intervention(s). f. Details about missing data Discussion What does it mean? a. Key findings, including relevance to the rationale and specific aims		they were addressed, including, but not limited to, formal ethics review
13. Resultstime-line diagram, flow chart, or table), including modifications made to the intervention during the projectb. Details of the process measures and outcome c. Contextual elements that interacted with the intervention(s) d. Observed associations between outcomes, interventions, and relevant 	Results	
a. Key findings, including relevance to the <u>rationale</u> and specific aims	13. Results	 time-line diagram, flow chart, or table), including modifications made to the intervention during the project b. Details of the process measures and outcome c. Contextual elements that interacted with the intervention(s) d. Observed associations between outcomes, interventions, and relevant contextual elements e. Unintended consequences such as unexpected benefits, problems, failures, or costs associated with the intervention(s).
	Discussion	What does it mean?
	14. Summary	

1 2	
3 4 5 6 7 8 9 10	1
11 12 13 14 15 16	1
17 18 19 20 21 22]
23 24	0
25 26 27	1
28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59	

15. Interpretation	 a. Nature of the association between the intervention(s) and the outcomes b. Comparison of results with findings from other publications c. Impact of the project on people and systems d. Reasons for any differences between observed and anticipated outcomes, including the influence of context e. Costs and strategic trade-offs, including opportunity costs
16. Limitations	 a. Limits to the <u>generalizability</u> of the work b. Factors that might have limited <u>internal validity</u> such as confounding, bias, or imprecision in the design, methods, measurement, or analysis c. Efforts made to minimize and adjust for limitations
17. Conclusions	 a. Usefulness of the work b. Sustainability c. Potential for spread to other <u>contexts</u> d. Implications for practice and for further study in the field e. Suggested next steps
Other information	
18. Funding	Sources of funding that supported this work. Role, if any, of the funding organization in the design, implementation, interpretation, and reporting

Table 2. Glossary of key terms used in SQUIRE 2.0. This Glossary provides the intended meaning of selected words and phrases as they are used in the SQUIRE 2.0 Guidelines. They may, and often do, have different meanings in other disciplines, situations, and settings.

Assumptions

Reasons for choosing the activities and tools used to bring about changes in healthcare services at the system level.

Context

Physical and sociocultural makeup of the local environment (for example, external environmental factors, organizational dynamics, collaboration, resources, leadership, and the like), and the interpretation of these factors ("sense-making") by the healthcare delivery professionals, patients, and caregivers that can affect the effectiveness and generalizability of intervention(s).

Ethical aspects

The value of <u>system-level initiatives</u> relative to their potential for harm, burden, and cost to the stakeholders. Potential harms particularly associated with efforts to improve the quality, safety, and value of healthcare services include <u>opportunity costs</u>, invasion of privacy, and staff distress resulting from disclosure of poor performance.

Generalizability

The likelihood that the <u>intervention(s)</u> in a particular report would produce similar results in other settings, situations, or environments (also referred to as external validity).

Healthcare improvement

Any systematic effort intended to raise the quality, safety, and value of healthcare services, usually done at the <u>system</u> level. We encourage the use of this phrase rather than "quality improvement," which often refers to more narrowly defined approaches.

Inferences

The meaning of findings or data, as interpreted by the stakeholders in healthcare services – improvers, healthcare delivery professionals, and/or patients and families

Initiative

A broad term that can refer to organization-wide programs, narrowly focused projects, or the details of specific interventions (for example, planning, execution, and assessment)

Internal validity

Demonstrable, credible evidence for efficacy (meaningful impact or change) resulting from introduction of a specific intervention into a particular healthcare system.

Intervention(s)

The specific activities and tools introduced into a healthcare <u>system</u> with the aim of changing its performance for the better. Complete description of an intervention includes its inputs, internal activities, and outputs (in the form of a logic model, for example), and the mechanism(s) by which these components are expected to produce changes in a <u>system's</u> performance.

Opportunity costs

Loss of the ability to perform other tasks or meet other responsibilities resulting from the diversion of resources needed to introduce, test, or sustain a particular <u>improvement</u> initiative

Problem

Meaningful disruption, failure, inadequacy, distress, confusion or other dysfunction in a healthcare service delivery <u>system</u> that adversely affects patients, staff, or the <u>system</u> as a whole, or that prevents care from reaching its full potential

Process

The routines and other activities through which healthcare services are delivered

Rationale

Explanation of why particular <u>intervention(s)</u> were chosen and why it was expected to work, be sustainable, and be replicable elsewhere.

Systems

The interrelated structures, people, processes, and activities that together create healthcare services for and with individual patients and populations. For example, systems exist from the personal self-care system of a patient, to the individual provider-patient dyad system, to the microsystem, to the macrosystem, and all the way to the market/social/insurance system. These levels are nested within each other.

Theory or theories

Any "reason-giving" account that asserts causal relationships between variables (causal theory) or that makes sense of an otherwise obscure <u>process</u> or situation (explanatory theory). Theories come in many forms, and serve different purposes in the phases of <u>improvement</u> work. It is important to be explicit and well-founded about any informal and formal theory (or theories) that are used.